<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="review-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">870282</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2022.870282</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>
<italic>Aconiti Lateralis Radix Praeparata</italic> as Potential Anticancer Herb: Bioactive Compounds and Molecular Mechanisms</article-title>
<alt-title alt-title-type="left-running-head">Zhang et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<italic>Aconiti Lateralis Radix Praeparata</italic>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zhang</surname>
<given-names>Wen</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1667087/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lu</surname>
<given-names>Chaoying</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cai</surname>
<given-names>Shuhui</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Feng</surname>
<given-names>Yaru</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shan</surname>
<given-names>Jinjun</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/543945/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Di</surname>
<given-names>Liuqing</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>School of Pharmacy</institution>, <institution>Nanjing University of Chinese Medicine</institution>, <addr-line>Nanjing</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Jiangsu Engineering Research Center for Efficient Delivery System of TCM</institution>, <addr-line>Nanjing</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Jiangsu Key Laboratory of Pediatric Respiratory Disease</institution>, <institution>Institute of Pediatrics</institution>, <institution>Nanjing University of Chinese Medicine</institution>, <addr-line>Nanjing</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/407682/overview">Linlin Lu</ext-link>, Guangzhou University of Chinese Medicine, China</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1626557/overview">Mansi Wu</ext-link>, Jinan University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/385430/overview">Wei Huang</ext-link>, Chinese Academy of Medical Sciences and Peking Union Medical College, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Wen Zhang, <email>wenzhang@njucm.edu.cn</email>; Liuqing Di, <email>diliuqing@njucm.edu.cn</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work and share first authorship</p>
</fn>
<fn fn-type="other">
<p>This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>18</day>
<month>05</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>870282</elocation-id>
<history>
<date date-type="received">
<day>06</day>
<month>02</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>03</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Zhang, Lu, Cai, Feng, Shan and Di.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Zhang, Lu, Cai, Feng, Shan and Di</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>
<italic>Aconiti Lateralis Radix Praeparata</italic> (Fuzi in Chinese) is a traditional herbal medicine widely used in China and other Asian countries. In clinical practice, it is often used to treat heart failure, rheumatoid arthritis, and different kinds of pains. Fuzi extract and its active ingredients exert considerable anticancer, anti-inflammatory, and analgesic effects. The main chemical substances of Fuzi include alkaloids, polysaccharides, flavonoids, fatty acids, and sterols. Among of them, alkaloids and polysaccharides are responsible for the anticancer efficacy. Most bioactive alkaloids in Fuzi possess C<sub>19</sub> diterpenoid mother nucleus and these natural products show great potential for cancer therapy. Moreover, polysaccharides exert extraordinary tumor-suppressive functions. This review comprehensively summarized the active ingredients, antineoplastic effects, and molecular mechanisms of Fuzi by searching PubMed, Web of Science, ScienceDirect, and CNKI. The anticancer effects are largely attributed to inducing apoptosis and autophagy, inhibiting proliferation, migration and invasion, regulating body immunity, affecting energy metabolism, as well as reversing multidrug resistance. Meanwhile, several signaling pathways and biological processes are mainly involved, such as NF-&#x3ba;B, EMT, HIF-1, p38 MAPK, PI3K/AKT/mTOR, and TCA cycle. Collectively, alkaloids and polysaccharides in Fuzi might serve as attractive therapeutic candidates for the development of anticancer drugs. This review would lay a foundation and provide a basis for further basic research and clinical application of Fuzi.</p>
</abstract>
<kwd-group>
<kwd>
<italic>Aconiti Lateralis Radix Praeparata</italic>
</kwd>
<kwd>Fuzi</kwd>
<kwd>alkaloid</kwd>
<kwd>polysaccharide</kwd>
<kwd>anticancer</kwd>
<kwd>mechanism</kwd>
</kwd-group>
<contract-sponsor id="cn001">National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/501100001809</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">Natural Science Foundation of Jiangsu Province<named-content content-type="fundref-id">10.13039/501100004608</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>With the incidence increasing year by year, malignant tumor has become one of the main factors that jeopardize human health. Currently, researchers are working on pathophysiology of cancer and seeking effective treatments, intending to continuously advance the progress of cancer therapy (<xref ref-type="bibr" rid="B9">Bray et al., 2018</xref>; <xref ref-type="bibr" rid="B57">Lee et al., 2018</xref>). Surgery, chemotherapy, and radiation are common methods to treat cancer. However, these treatments are often accompanied with adverse reactions and complications, such as fatigue, nausea, and pain. In addition, some commonly used chemotherapeutic drugs also have drug resistance, which hinders the treatment process (<xref ref-type="bibr" rid="B29">Gainor et al., 2016</xref>; <xref ref-type="bibr" rid="B30">Gainor et al., 2017</xref>). For the past few years, natural compounds extracted from plants have become more and more popular owing to their excellent anticancer effect and low toxicity. Many researchers are also committed to exploring natural compounds with anticancer activity as substitutes for chemotherapy (<xref ref-type="bibr" rid="B39">Guo et al., 2019</xref>; <xref ref-type="bibr" rid="B87">Rashid et al., 2019</xref>; <xref ref-type="bibr" rid="B68">Liu et al., 2021</xref>; <xref ref-type="bibr" rid="B95">Singh et al., 2021</xref>).</p>
<p>Fuzi is the processed product of the daughter root of <italic>Aconitum carmichaeli</italic> Debx, which has hot-natured and pungent in flavor recorded in <italic>Shennong&#x2019;s Classic of Materia Medica</italic> firstly. Fuzi has been used as a traditional Chinese medicine (TCM) in China for centuries and offers therapeutic potential for heart failure, rheumatoid arthritis, gastroenteritis, depression, and other diseases (<xref ref-type="bibr" rid="B121">Wu et al., 2018</xref>; <xref ref-type="bibr" rid="B78">Meng-Qi Yang et al., 2019</xref>; <xref ref-type="bibr" rid="B130">Zhang et al., 2021</xref>). Constituents such as alkaloids, polysaccharides, flavonoids, fatty acids, ceramides, and trace elements are the material basis for Fuzi to exert a variety of functions (<xref ref-type="bibr" rid="B120">Wu et al., 2014</xref>). Studies indicated that alkaloids and polysaccharides in Fuzi possessed anticancer activity, which could availably induce tumor cell apoptosis, restrain cell proliferation, and regulate immunity. In addition, other compounds such as deltoin, sitosterol, neokadsuranic acid B, and 11,14-eicosadienoic acid were speculated to possess the potential to target PI3K/AKT pathway for anticancer effects under the prediction of network pharmacology and molecular docking (<xref ref-type="bibr" rid="B122">Xin Yang et al., 2019</xref>). In view of this, Fuzi alkaloids and polysaccharides have sparked increasing interest in the application of cancer therapy. A comprehensive perception of anticancer mechanisms is a prerequisite to the design of rational therapeutics. Therefore, the mechanisms account for the anticancer efficacies on Fuzi alkaloids and polysaccharides are required to be discussed and concluded. This review would provide a new recognition of Fuzi in treating cancer and be of great significance for guiding clinical medication and developing novel antineoplastic drugs.</p>
</sec>
<sec id="s2">
<title>Fuzi Alkaloids</title>
<p>Pharmacological studies indicate that alkaloids in Fuzi have the effects of anti-inflammation, anticancer, immunoregulation, etc. (<xref ref-type="bibr" rid="B62">Li et al., 2019</xref>). The alkaloids in Fuzi are mainly diterpenoid ones, which are classified into three categories according to the number of carbon atoms on the mother nucleus: C<sub>18</sub>, C<sub>19</sub>, and C<sub>20</sub> diterpenoid alkaloids (<xref ref-type="bibr" rid="B134">Zhu, 2008</xref>). Studies have demonstrated that diterpenoid alkaloids exert anticancer effects.</p>
<sec id="s2-1">
<title>C<sub>18</sub> Diterpenoid Alkaloids</title>
<p>Lappaconitine, a kind of C<sub>18</sub> diterpenoid alkaloids, inhibited the proliferation of lung cancer A549 cells and induced cell apoptosis (<xref ref-type="bibr" rid="B94">Sheng et al., 2014</xref>; <xref ref-type="bibr" rid="B26">Fang, 2018</xref>). <italic>In vivo</italic> investigation revealed that the tumor inhibitory rate of mice bearing liver cancer is 11.20&#x2013;53.08%; meanwhile that of mice bearing S180 sarcoma cells was 29.81&#x2013;53.96% after the administration of lappaconitine (<xref ref-type="bibr" rid="B63">Lin et al., 2005</xref>). Besides, lappaconitine was widely used in the analgesia of various cancers with high safety and no addiction (<xref ref-type="bibr" rid="B127">Zhang et al., 2016</xref>; <xref ref-type="bibr" rid="B102">Sun, 2017</xref>). <xref ref-type="fig" rid="F1">Figure 1</xref> displays the structural formula of lappaconitine and the mother nucleus of C<sub>18</sub> diterpenoid alkaloids in Fuzi.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Structures of lappaconitine and C<sub>18</sub> diterpenoid alkaloids in Fuzi.</p>
</caption>
<graphic xlink:href="fphar-13-870282-g001.tif"/>
</fig>
</sec>
<sec id="s2-2">
<title>C<sub>19</sub> Diterpenoid Alkaloids</title>
<p>Most of the constituents with antineoplastic efficacies in Fuzi are C<sub>19</sub> diterpenoid alkaloids. Apart from the bioactivity, these compounds are also poisonous, which lead to cardiotoxicity and neurotoxicity. Three main C<sub>19</sub>-diester-diterpenoid alkaloids (DDAs) were responsible for the toxicity of Fuzi, namely, aconitine, mesaconitine, and hypaconitine. Studies have shown that the median lethal dose (LD<sub>50</sub>) of single-dose oral aconitine in mice is 1.0&#x2013;1.8&#xa0;mg/kg, while the LD<sub>50</sub> of mesaconitine and hypaconitine are 1.9 and 5.8&#xa0;mg/kg, respectively. The dose&#x2013;effect relationship of DDAs on clinical therapy remains to be further studied (<xref ref-type="bibr" rid="B109">Wada et al., 2005</xref>; <xref ref-type="bibr" rid="B96">Singhuber et al., 2009</xref>). So far, nearly 80 kinds of C<sub>19</sub> diterpenoid alkaloids have been extracted (<xref ref-type="bibr" rid="B104">Tang et al., 2017</xref>; <xref ref-type="bibr" rid="B129">Zhang et al., 2020</xref>). The mother nucleus of C<sub>19</sub> diterpenoid alkaloids is shown in <xref ref-type="fig" rid="F2">Figure 2</xref>, and natural C<sub>19</sub> diterpenoid alkaloids with anticancer activity are listed in <xref ref-type="table" rid="T1">Table 1</xref>. As shown in <xref ref-type="table" rid="T1">Table 1</xref>, the common ingredients of Fuzi, such as aconitine, mesaconitine, hypaconitine, benzoylaconitine, and neoline, have been proved to exhibit anticancer functions. Furthermore, the derivatives of C<sub>19</sub> diterpenoid alkaloids could also repress the growth of tumor cells (<xref ref-type="bibr" rid="B88">Ren et al., 2017</xref>). The antiproliferative effects of C<sub>19</sub> diterpene alkaloids and their derivatives on different tumor cell lines are summarized in <xref ref-type="table" rid="T2">Table 2</xref>. Among the tested cells, the HepG2 cells were highly sensitive to C<sub>19</sub> diterpenoid alkaloids as well as their derivatives. By analyzing the structure&#x2013;activity relationship, it was found that the alkaloids with stronger cytotoxicity, such as aconitine, mesaconitine, hypaconitine, crassicauline A, oxonitine, and dexyaconitine, were associated with the acetoxy group (OAc) on the substituent of R6, suggesting that the positions and species of substituents on the mother nucleus were closely related to the antitumor activity of C<sub>19</sub> diterpenoid alkaloid.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Structures of C<sub>19</sub> diterpenoid alkaloids in Fuzi.</p>
</caption>
<graphic xlink:href="fphar-13-870282-g002.tif"/>
</fig>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Structures of natural C<sub>19</sub> diterpenoid alkaloids with anticancer activities in Fuzi.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">No</th>
<th align="center">Compounds</th>
<th align="center">R<sub>1</sub>
</th>
<th align="center">R<sub>2</sub>
</th>
<th align="center">R<sub>3</sub>
</th>
<th align="center">R<sub>4</sub>
</th>
<th align="center">R<sub>5</sub>
</th>
<th align="center">R<sub>6</sub>
</th>
<th align="center">R<sub>7</sub>
</th>
<th align="center">R<sub>8</sub>
</th>
<th align="center">R<sub>9</sub>
</th>
<th align="center">R<sub>10</sub>
</th>
<th align="center">Reference</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">1</td>
<td>Aconitine</td>
<td>OMe</td>
<td>C<sub>2</sub>H<sub>5</sub>
</td>
<td>OH</td>
<td>OMe</td>
<td>OMe</td>
<td>OA<sub>C</sub>
</td>
<td>OB<sub>Z</sub>
</td>
<td>OH</td>
<td>OH</td>
<td>OMe</td>
<td>
<xref ref-type="bibr" rid="B66">Liu et al. (2004)</xref>; <xref ref-type="bibr" rid="B32">Gao et al. (2012a)</xref>; <xref ref-type="bibr" rid="B86">Qian (2015)</xref>
</td>
</tr>
<tr>
<td align="left">2</td>
<td>Crassicauline A</td>
<td>OMe</td>
<td>C<sub>2</sub>H<sub>5</sub>
</td>
<td>H</td>
<td>OMe</td>
<td>OMe</td>
<td>OA<sub>C</sub>
</td>
<td>OAs</td>
<td>OH</td>
<td>H</td>
<td>OMe</td>
<td>
<xref ref-type="bibr" rid="B32">Gao et al. (2012a)</xref>
</td>
</tr>
<tr>
<td align="left">3</td>
<td>Deoxyaconitine</td>
<td>OMe</td>
<td>C<sub>2</sub>H<sub>5</sub>
</td>
<td>H</td>
<td>OMe</td>
<td>OMe</td>
<td>OA<sub>C</sub>
</td>
<td>OB<sub>Z</sub>
</td>
<td>OH</td>
<td>OH</td>
<td>OMe</td>
<td>
<xref ref-type="bibr" rid="B32">Gao et al. (2012a)</xref>
</td>
</tr>
<tr>
<td align="left">4</td>
<td>Hypaconitine</td>
<td>OMe</td>
<td>CH<sub>3</sub>
</td>
<td>H</td>
<td>OMe</td>
<td>OMe</td>
<td>OA<sub>C</sub>
</td>
<td>OB<sub>Z</sub>
</td>
<td>OH</td>
<td>OH</td>
<td>OMe</td>
<td>
<xref ref-type="bibr" rid="B32">Gao et al. (2012a)</xref>
</td>
</tr>
<tr>
<td align="left">5</td>
<td>Mesaconitine</td>
<td>OMe</td>
<td>CH<sub>3</sub>
</td>
<td>OH</td>
<td>OMe</td>
<td>OMe</td>
<td>OA<sub>C</sub>
</td>
<td>OB<sub>Z</sub>
</td>
<td>OH</td>
<td>OH</td>
<td>OMe</td>
<td>
<xref ref-type="bibr" rid="B32">Gao et al. (2012a)</xref>
</td>
</tr>
<tr>
<td align="left">6</td>
<td>Oxonitine</td>
<td>OMe</td>
<td>CHO</td>
<td>H</td>
<td>OMe</td>
<td>OMe</td>
<td>OA<sub>C</sub>
</td>
<td>OB<sub>Z</sub>
</td>
<td>OH</td>
<td>OH</td>
<td>OMe</td>
<td>
<xref ref-type="bibr" rid="B32">Gao et al. (2012a)</xref>
</td>
</tr>
<tr>
<td align="left">7</td>
<td>Lipoaconitine</td>
<td>OMe</td>
<td>C<sub>2</sub>H<sub>5</sub>
</td>
<td>OH</td>
<td>OMe</td>
<td>OMe</td>
<td>O-Lipo</td>
<td>OB<sub>Z</sub>
</td>
<td>OH</td>
<td>OH</td>
<td>OMe</td>
<td>
<xref ref-type="bibr" rid="B113">Wada and Yamashita, (2019)</xref>
</td>
</tr>
<tr>
<td align="left">8</td>
<td>Lipomesaconitine</td>
<td>OMe</td>
<td>CH<sub>3</sub>
</td>
<td>OH</td>
<td>OMe</td>
<td>OMe</td>
<td>O-Lipo</td>
<td>OB<sub>Z</sub>
</td>
<td>OH</td>
<td>OH</td>
<td>OMe</td>
<td>
<xref ref-type="bibr" rid="B113">Wada and Yamashita, (2019)</xref>
</td>
</tr>
<tr>
<td align="left">9</td>
<td>Lipojesaconitine</td>
<td>OMe</td>
<td>C<sub>2</sub>H<sub>5</sub>
</td>
<td>OH</td>
<td>OMe</td>
<td>OMe</td>
<td>O-Lipo</td>
<td>OAs</td>
<td>OH</td>
<td>OH</td>
<td>OMe</td>
<td>
<xref ref-type="bibr" rid="B113">Wada and Yamashita, (2019)</xref>
</td>
</tr>
<tr>
<td align="left">10</td>
<td>Neoline</td>
<td>OH</td>
<td>C<sub>2</sub>H<sub>5</sub>
</td>
<td>H</td>
<td>OMe</td>
<td>OMe</td>
<td>OH</td>
<td>OH</td>
<td>H</td>
<td>H</td>
<td>OMe</td>
<td>
<xref ref-type="bibr" rid="B41">Hao (2014)</xref>
</td>
</tr>
<tr>
<td align="left">11</td>
<td>Benzoylaconitine</td>
<td>OMe</td>
<td>C<sub>2</sub>H<sub>5</sub>
</td>
<td>OH</td>
<td>OMe</td>
<td>OMe</td>
<td>OH</td>
<td>OB<sub>Z</sub>
</td>
<td>OH</td>
<td>OH</td>
<td>OMe</td>
<td>
<xref ref-type="bibr" rid="B92">Shao et al. (2019)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Cytotoxicity of C<sub>19</sub> diterpenoid alkaloids and their derivatives in different cancer cell lines.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">No</th>
<th align="center">Compounds</th>
<th align="center">Cell lines</th>
<th align="center">Cancer types</th>
<th align="center">IC<sub>50</sub> (&#x3bc;M)</th>
<th align="center">Reference</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="5" align="left">1</td>
<td rowspan="5" align="left">Aconitine</td>
<td align="left">Hepal-6</td>
<td align="left">Liver cancer</td>
<td align="char" char=".">590.03</td>
<td align="left">
<xref ref-type="bibr" rid="B86">Qian (2015)</xref>
</td>
</tr>
<tr>
<td align="left">KBv200</td>
<td align="left">Drug-resistant KB subline</td>
<td align="char" char=".">348.29</td>
<td align="left">
<xref ref-type="bibr" rid="B66">Liu et al. (2004)</xref>
</td>
</tr>
<tr>
<td align="left">HCT8</td>
<td align="left">Colon cancer</td>
<td align="char" char=".">0.0812</td>
<td align="left">
<xref ref-type="bibr" rid="B32">Gao et al. (2012a)</xref>
</td>
</tr>
<tr>
<td align="left">MCF7</td>
<td align="left">Breast cancer</td>
<td align="char" char=".">0.0245</td>
<td rowspan="2" align="left"/>
</tr>
<tr>
<td align="left">HepG2</td>
<td align="left">Liver cancer</td>
<td align="char" char=".">0.0085</td>
</tr>
<tr>
<td rowspan="3" align="left">2</td>
<td rowspan="3" align="left">Crassicauline A</td>
<td align="left">HCT8</td>
<td align="left">Colon cancer</td>
<td align="char" char=".">0.1645</td>
<td rowspan="3" align="left">
<xref ref-type="bibr" rid="B32">Gao et al. (2012a)</xref>
</td>
</tr>
<tr>
<td align="left">MCF7</td>
<td align="left">Breast cancer</td>
<td align="char" char=".">0.1286</td>
</tr>
<tr>
<td align="left">HepG2</td>
<td align="left">Liver cancer</td>
<td align="char" char=".">0.0236</td>
</tr>
<tr>
<td rowspan="3" align="left">3</td>
<td rowspan="3" align="left">Oxonitine</td>
<td align="left">HCT8</td>
<td align="left">Colon cancer</td>
<td align="char" char=".">0.2948</td>
<td rowspan="3" align="left">
<xref ref-type="bibr" rid="B32">Gao et al. (2012a)</xref>
</td>
</tr>
<tr>
<td align="left">MCF7</td>
<td align="left">Breast cancer</td>
<td align="char" char=".">0.0313</td>
</tr>
<tr>
<td align="left">HepG2</td>
<td align="left">Liver cancer</td>
<td align="char" char=".">0.0861</td>
</tr>
<tr>
<td rowspan="3" align="left">4</td>
<td rowspan="3" align="left">Deoxyaconitine</td>
<td align="left">HCT8</td>
<td align="left">Colon cancer</td>
<td align="char" char=".">0.0514</td>
<td rowspan="3" align="left">
<xref ref-type="bibr" rid="B32">Gao et al. (2012a)</xref>
</td>
</tr>
<tr>
<td align="left">MCF7</td>
<td align="left">Breast cancer</td>
<td align="char" char=".">0.1035</td>
</tr>
<tr>
<td align="left">HepG2</td>
<td align="left">Liver cancer</td>
<td align="char" char=".">0.0921</td>
</tr>
<tr>
<td rowspan="3" align="left">5</td>
<td rowspan="3" align="left">Hypaconitine</td>
<td align="left">HCT8</td>
<td align="left">Colon cancer</td>
<td align="char" char=".">0.1205</td>
<td rowspan="3" align="left">
<xref ref-type="bibr" rid="B32">Gao et al. (2012a)</xref>
</td>
</tr>
<tr>
<td align="left">MCF7</td>
<td align="left">Breast cancer</td>
<td align="char" char=".">0.0646</td>
</tr>
<tr>
<td align="left">HepG2</td>
<td align="left">Liver cancer</td>
<td align="char" char=".">0.0092</td>
</tr>
<tr>
<td rowspan="3" align="left">6</td>
<td rowspan="3" align="left">Mesaconitine</td>
<td align="left">HCT8</td>
<td align="left">Colon cancer</td>
<td align="char" char=".">0.1316</td>
<td rowspan="3" align="left">
<xref ref-type="bibr" rid="B32">Gao et al. (2012a)</xref>
</td>
</tr>
<tr>
<td align="left">MCF7</td>
<td align="left">Breast cancer</td>
<td align="char" char=".">0.0457</td>
</tr>
<tr>
<td align="left">HepG2</td>
<td align="left">Liver cancer</td>
<td align="char" char=".">0.0145</td>
</tr>
<tr>
<td rowspan="5" align="left">7</td>
<td rowspan="5" align="left">Lipomesaconitine</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="char" char=".">17.2</td>
<td rowspan="5" align="left">
<xref ref-type="bibr" rid="B113">Wada and Yamashita, (2019)</xref>
</td>
</tr>
<tr>
<td align="left">MDA-MB-231</td>
<td align="left">Breast cancer</td>
<td align="char" char=".">20.0</td>
</tr>
<tr>
<td align="left">MCF-7</td>
<td align="left">Breast cancer</td>
<td align="char" char=".">19.0</td>
</tr>
<tr>
<td align="left">KB</td>
<td align="left">Cervical carcinoma</td>
<td align="char" char=".">10.0</td>
</tr>
<tr>
<td align="left">KB-VIN</td>
<td align="left">Vincristine-resistant KB subline</td>
<td align="char" char=".">21.5</td>
</tr>
<tr>
<td rowspan="5" align="left">8</td>
<td rowspan="5" align="left">Lipoaconitine</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="char" char=".">17.4</td>
<td rowspan="5" align="left">
<xref ref-type="bibr" rid="B113">Wada and Yamashita, (2019)</xref>
</td>
</tr>
<tr>
<td align="left">MDA-MB-231</td>
<td align="left">Breast cancer</td>
<td align="char" char=".">15.5</td>
</tr>
<tr>
<td align="left">MCF-7</td>
<td align="left">Breast cancer</td>
<td align="char" char=".">16.0</td>
</tr>
<tr>
<td align="left">KB</td>
<td align="left">Cervical carcinoma</td>
<td align="char" char=".">13.7</td>
</tr>
<tr>
<td align="left">KB-VIN</td>
<td align="left">Vincristine-resistant KB subline</td>
<td align="char" char=".">20.3</td>
</tr>
<tr>
<td rowspan="5" align="left">9</td>
<td rowspan="5" align="left">Lipojesaconitine</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="char" char=".">7.3</td>
<td rowspan="5" align="left">
<xref ref-type="bibr" rid="B113">Wada and Yamashita, (2019)</xref>
</td>
</tr>
<tr>
<td align="left">MDA-MB-231</td>
<td align="left">Breast cancer</td>
<td align="char" char=".">6.0</td>
</tr>
<tr>
<td align="left">MCF-7</td>
<td align="left">Breast cancer</td>
<td align="char" char=".">6.7</td>
</tr>
<tr>
<td align="left">KB</td>
<td align="left">Cervical carcinoma</td>
<td align="char" char=".">6.0</td>
</tr>
<tr>
<td align="left">KB-VIN</td>
<td align="left">Vincristine-resistant KB subline</td>
<td align="char" char=".">18.6</td>
</tr>
<tr>
<td rowspan="3" align="left">10</td>
<td rowspan="3" align="left">8-O-Azeloyl-14-benzoylaconine</td>
<td align="left">HCT-15</td>
<td align="left">Colon cancer</td>
<td align="char" char=".">16.8</td>
<td rowspan="3" align="left">
<xref ref-type="bibr" rid="B17">Chodoeva et al. (2005)</xref>
</td>
</tr>
<tr>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="char" char=".">19.4</td>
</tr>
<tr>
<td align="left">MCF-7</td>
<td align="left">Breast cancer</td>
<td align="char" char=".">10.3</td>
</tr>
<tr>
<td rowspan="3" align="left">11</td>
<td rowspan="3" align="left">Neoline</td>
<td align="left">SGC-7901</td>
<td align="left">Gastric cancer</td>
<td align="char" char=".">37.55</td>
<td rowspan="3" align="left">
<xref ref-type="bibr" rid="B41">Hao (2014)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2</td>
<td align="left">Liver cancer</td>
<td align="char" char=".">28.36</td>
</tr>
<tr>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="char" char=".">34.74</td>
</tr>
<tr>
<td rowspan="3" align="left">12</td>
<td rowspan="3" align="left">14-O-Acetylneoline</td>
<td align="left">SGC-7901</td>
<td align="left">Gastric cancer</td>
<td align="char" char=".">16.97</td>
<td rowspan="3" align="left">
<xref ref-type="bibr" rid="B41">Hao (2014)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2</td>
<td align="left">Liver cancer</td>
<td align="char" char=".">33.76</td>
</tr>
<tr>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="char" char=".">18.75</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-3">
<title>C<sub>20</sub> Diterpenoid Alkaloids</title>
<p>C<sub>20</sub> diterpenoid alkaloid is another kind of alkaloid in Fuzi. Songorine, a natural C<sub>20</sub> diterpenoid alkaloid found in Fuzi, has been proved to be antineoplastic. Studies revealed that songorine suppressed the proliferation of HepG2 cells effectively and increased apoptosis at both early and late stages (<xref ref-type="bibr" rid="B101">Sun et al., 2018</xref>). Moreover, songorine manifested other biological functions such as analgesic, anti-arrhythmic, and anti-inflammatory activities (<xref ref-type="bibr" rid="B54">Khan et al., 2018</xref>). <xref ref-type="fig" rid="F3">Figure 3</xref> shows the structural formula of songorine and two types of mother nucleus of C<sub>20</sub> diterpenoid alkaloids in Fuzi. Based on the structure of natural C<sub>20</sub> diterpenoid alkaloids, researchers synthesized a series of derivatives and tested their antiproliferative activity on different tumor cell lines. The results revealed that most derivatives exhibited considerable cytotoxic effects (<xref ref-type="table" rid="T3">Table 3</xref>). Malignant glioma A172 cells and lung cancer A549 cells were highly sensitive to most of C<sub>20</sub> diterpenoid alkaloid derivatives. Of note, certain synthetic alkaloid derivatives displayed stronger anticancer activity than the natural ones. It was suggested that diterpenoid alkaloids demonstrated great potentiality in cancer treatment.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Structures of songorine and C<sub>20</sub> diterpenoid alkaloids in Fuzi.</p>
</caption>
<graphic xlink:href="fphar-13-870282-g003.tif"/>
</fig>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Cytotoxicity of C<sub>20</sub> diterpenoid alkaloids and their derivatives in different cancer cell lines.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">No</th>
<th align="center">Compounds</th>
<th align="center">Cell lines</th>
<th align="center">Cancer types</th>
<th align="center">IC<sub>50</sub> (&#x3bc;M)</th>
<th align="center">Reference</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="3" align="left">1</td>
<td rowspan="3" align="left">Atisinium chloride</td>
<td align="left">AGS</td>
<td align="left">Gastric cancer</td>
<td align="left">0.44</td>
<td rowspan="3" align="left">
<xref ref-type="bibr" rid="B134">Zhu (2008)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2</td>
<td align="left">Liver cancer</td>
<td align="left">66.69</td>
</tr>
<tr>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">2.29</td>
</tr>
<tr>
<td align="left">2</td>
<td align="left">15-Acetylsongoramine</td>
<td align="left">HepG2</td>
<td align="left">Liver cancer</td>
<td align="left">0.59</td>
<td align="left">
<xref ref-type="bibr" rid="B32">Gao et al. (2012a)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="left">3</td>
<td rowspan="3" align="left">Songorine</td>
<td align="left">SGC-7901</td>
<td align="left">Gastric cancer</td>
<td align="left">46.55</td>
<td rowspan="3" align="left">
<xref ref-type="bibr" rid="B41">Hao (2014)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2</td>
<td align="left">Liver cancer</td>
<td align="left">87.72</td>
</tr>
<tr>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">61.90</td>
</tr>
<tr>
<td rowspan="3" align="left">4</td>
<td rowspan="3" align="left">12-Epi-napelline</td>
<td align="left">SGC-7901</td>
<td align="left">Gastric cancer</td>
<td align="left">64.79</td>
<td rowspan="3" align="left">
<xref ref-type="bibr" rid="B41">Hao (2014)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2</td>
<td align="left">Liver cancer</td>
<td align="left">96.99</td>
</tr>
<tr>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">65.91</td>
</tr>
<tr>
<td rowspan="3" align="left">5</td>
<td rowspan="3" align="left">12-Epi-dehydronapelline</td>
<td align="left">SGC-7901</td>
<td align="left">Gastric cancer</td>
<td align="left">65.00</td>
<td rowspan="3" align="left">
<xref ref-type="bibr" rid="B41">Hao (2014)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2</td>
<td align="left">Liver cancer</td>
<td align="left">46.63</td>
</tr>
<tr>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">76.50</td>
</tr>
<tr>
<td align="left">6</td>
<td align="left">12-Acetylluciculine</td>
<td align="left">A172</td>
<td align="left">Malignant glioma</td>
<td align="left">13.95</td>
<td align="left">
<xref ref-type="bibr" rid="B110">Wada et al. (2007)</xref>
</td>
</tr>
<tr>
<td align="left">7</td>
<td align="left">6,11-Dibenzoylpseudokobusine</td>
<td align="left">A172</td>
<td align="left">Malignant glioma</td>
<td align="left">2.42</td>
<td align="left">
<xref ref-type="bibr" rid="B110">Wada et al. (2007)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="left">8</td>
<td rowspan="3" align="left">11-Veratroylpseudokobusine</td>
<td align="left">A172</td>
<td align="left">Malignant glioma</td>
<td align="left">2.52</td>
<td align="left">
<xref ref-type="bibr" rid="B110">Wada et al. (2007)</xref>
</td>
</tr>
<tr>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">3.5</td>
<td align="left">
<xref ref-type="bibr" rid="B42">Hazawa et al. (2009)</xref>
</td>
</tr>
<tr>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">4.07</td>
<td align="left">
<xref ref-type="bibr" rid="B111">Wada et al. (2011)</xref>
</td>
</tr>
<tr>
<td rowspan="6" align="left">9</td>
<td rowspan="6" align="left">11-Cinnamoylpseudokobusine</td>
<td align="left">A172</td>
<td align="left">Malignant glioma</td>
<td align="left">1.94</td>
<td align="left">
<xref ref-type="bibr" rid="B110">Wada et al. (2007)</xref>
</td>
</tr>
<tr>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">5.1</td>
<td align="left">
<xref ref-type="bibr" rid="B42">Hazawa et al. (2009)</xref>
</td>
</tr>
<tr>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">8.4 (GI<sub>50</sub>)</td>
<td align="left">
<xref ref-type="bibr" rid="B112">Wada et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">DU145</td>
<td align="left">Prostate cancer</td>
<td align="left">6.5 (GI<sub>50</sub>)</td>
<td rowspan="3" align="left"/>
</tr>
<tr>
<td align="left">KB</td>
<td align="left">Nasopharyngeal carcinoma</td>
<td align="left">7.0 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td align="left">KB-VIN</td>
<td align="left">Vincristine-resistant KB subline</td>
<td align="left">6.4 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td rowspan="4" align="left">10</td>
<td rowspan="4" align="left">11-Anisoylpseudokobusine</td>
<td align="left">A172</td>
<td align="left">Malignant glioma</td>
<td align="left">2.80</td>
<td align="left">
<xref ref-type="bibr" rid="B110">Wada et al. (2007)</xref>
</td>
</tr>
<tr>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">1.7</td>
<td align="left">
<xref ref-type="bibr" rid="B42">Hazawa et al. (2009)</xref>
</td>
</tr>
<tr>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">2.20</td>
<td align="left">
<xref ref-type="bibr" rid="B111">Wada et al. (2011)</xref>
</td>
</tr>
<tr>
<td align="left">Raji</td>
<td align="left">Lymphoma</td>
<td align="left">5.18</td>
<td align="left">
<xref ref-type="bibr" rid="B43">Hazawa et al. (2011)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">11</td>
<td rowspan="2" align="left">11-p-Nitrobenzoylpseudokobusine</td>
<td align="left">A172</td>
<td align="left">Malignant glioma</td>
<td align="left">3.13</td>
<td align="left">
<xref ref-type="bibr" rid="B110">Wada et al. (2007)</xref>
</td>
</tr>
<tr>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">3.5</td>
<td align="left">
<xref ref-type="bibr" rid="B42">Hazawa et al. (2009)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">12</td>
<td rowspan="2" align="left">11-(m-Trifluoromethylbenzoyl)pseudokobusine</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">4.4</td>
<td align="left">
<xref ref-type="bibr" rid="B42">Hazawa et al. (2009)</xref>
</td>
</tr>
<tr>
<td align="left">Raji</td>
<td align="left">Lymphoma</td>
<td align="left">4.39</td>
<td align="left">
<xref ref-type="bibr" rid="B43">Hazawa et al. (2011)</xref>
</td>
</tr>
<tr>
<td align="left">13</td>
<td align="left">6,11-Dianisoylpseudokobusine</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">3.68</td>
<td align="left">
<xref ref-type="bibr" rid="B111">Wada et al. (2011)</xref>
</td>
</tr>
<tr>
<td align="left">14</td>
<td align="left">11,15-Dianisoylpseudokobusine</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">1.72</td>
<td align="left">
<xref ref-type="bibr" rid="B111">Wada et al. (2011)</xref>
</td>
</tr>
<tr>
<td align="left">15</td>
<td align="left">11-p-Nitrobenzoate</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">5.08</td>
<td align="left">
<xref ref-type="bibr" rid="B111">Wada et al. (2011)</xref>
</td>
</tr>
<tr>
<td align="left">16</td>
<td align="left">11,15-Di-p-nitrobenzoate</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">2.66</td>
<td align="left">
<xref ref-type="bibr" rid="B111">Wada et al. (2011)</xref>
</td>
</tr>
<tr>
<td align="left">17</td>
<td align="left">11-Cinnamate</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">4.24</td>
<td align="left">
<xref ref-type="bibr" rid="B111">Wada et al. (2011)</xref>
</td>
</tr>
<tr>
<td align="left">18</td>
<td align="left">11-m-Trifluoromethylbenzoate</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">4.67</td>
<td align="left">
<xref ref-type="bibr" rid="B111">Wada et al. (2011)</xref>
</td>
</tr>
<tr>
<td align="left">19</td>
<td align="left">11-Anisoylkobusine</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">11.42</td>
<td align="left">
<xref ref-type="bibr" rid="B111">Wada et al. (2011)</xref>
</td>
</tr>
<tr>
<td align="left">20</td>
<td align="left">11-(p-Trifluoromethylbenzoyl)kobusine</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">5.44</td>
<td align="left">
<xref ref-type="bibr" rid="B111">Wada et al. (2011)</xref>
</td>
</tr>
<tr>
<td align="left">21</td>
<td align="left">11-(m-Trifluoromethylbenzoyl)kobusine</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">3.75</td>
<td align="left">
<xref ref-type="bibr" rid="B111">Wada et al. (2011)</xref>
</td>
</tr>
<tr>
<td align="left">22</td>
<td align="left">11,15-Di-p-nitrobenzoylkobusine</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">3.02</td>
<td align="left">
<xref ref-type="bibr" rid="B111">Wada et al. (2011)</xref>
</td>
</tr>
<tr>
<td rowspan="4" align="left">23</td>
<td rowspan="4" align="left">11,15-Dibenzoylkobusine</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">8.4 (GI<sub>50</sub>)</td>
<td rowspan="4" align="left">
<xref ref-type="bibr" rid="B112">Wada et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">DU145</td>
<td align="left">Prostate cancer</td>
<td align="left">9.3 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td align="left">KB</td>
<td align="left">Nasopharyngeal carcinoma</td>
<td align="left">6.0 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td align="left">KB-VIN</td>
<td align="left">Vincristine-resistant KB subline</td>
<td align="left">7.5 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td rowspan="4" align="left">24</td>
<td rowspan="4" align="left">11,15-Dianisoylkobusine</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">6.7 (GI<sub>50</sub>)</td>
<td rowspan="4" align="left">
<xref ref-type="bibr" rid="B112">Wada et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">DU145</td>
<td align="left">Prostate cancer</td>
<td align="left">7.1 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td align="left">KB</td>
<td align="left">Nasopharyngeal carcinoma</td>
<td align="left">5.3 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td align="left">KB-VIN</td>
<td align="left">Vincristine-resistant KB subline</td>
<td align="left">5.2 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td rowspan="4" align="left">25</td>
<td rowspan="4" align="left">11,15-Di-(4-nitrobenzoyl)kobusine</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">6.9 (GI<sub>50</sub>)</td>
<td rowspan="4" align="left">
<xref ref-type="bibr" rid="B112">Wada et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">DU145</td>
<td align="left">Prostate cancer</td>
<td align="left">7.0 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td align="left">KB</td>
<td align="left">Nasopharyngeal carcinoma</td>
<td align="left">5.3 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td align="left">KB-VIN</td>
<td align="left">Vincristine-resistant KB subline</td>
<td align="left">5.5 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td rowspan="4" align="left">26</td>
<td rowspan="4" align="left">11,15-Di-(4-fluorobenzoyl)kobusine</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">8.1 (GI<sub>50</sub>)</td>
<td rowspan="4" align="left">
<xref ref-type="bibr" rid="B112">Wada et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">DU145</td>
<td align="left">Prostate cancer</td>
<td align="left">6.8 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td align="left">KB</td>
<td align="left">Nasopharyngeal carcinoma</td>
<td align="left">5.2 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td align="left">KB-VIN</td>
<td align="left">Vincristine-resistant KB subline</td>
<td align="left">7.1 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td rowspan="4" align="left">27</td>
<td rowspan="4" align="left">11,15-Di-(3-trifluoromethylcinnamoyl)kobusine</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">5.5 (GI<sub>50</sub>)</td>
<td rowspan="4" align="left">
<xref ref-type="bibr" rid="B112">Wada et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">DU145</td>
<td align="left">Prostate cancer</td>
<td align="left">6.2 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td align="left">KB</td>
<td align="left">Nasopharyngeal carcinoma</td>
<td align="left">4.1 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td align="left">KB-VIN</td>
<td align="left">Vincristine-resistant KB subline</td>
<td align="left">3.1 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td rowspan="4" align="left">28</td>
<td rowspan="4" align="left">11,15-Dibenzoylpseudokobusine</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">8.8 (GI<sub>50</sub>)</td>
<td rowspan="4" align="left">
<xref ref-type="bibr" rid="B112">Wada et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">DU145</td>
<td align="left">Prostate cancer</td>
<td align="left">7.6 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td align="left">KB</td>
<td align="left">Nasopharyngeal carcinoma</td>
<td align="left">5.2 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td align="left">KB-VIN</td>
<td align="left">Vincristine-resistant KB subline</td>
<td align="left">6.3 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td rowspan="4" align="left">29</td>
<td rowspan="4" align="left">11-(4-Nitrobenzoyl)pseudokobusine</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">5.8 (GI<sub>50</sub>)</td>
<td rowspan="4" align="left">
<xref ref-type="bibr" rid="B112">Wada et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">DU145</td>
<td align="left">Prostate cancer</td>
<td align="left">7.2 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td align="left">KB</td>
<td align="left">Nasopharyngeal carcinoma</td>
<td align="left">6.4 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td align="left">KB-VIN</td>
<td align="left">Vincristine-resistant KB subline</td>
<td align="left">6.4 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td rowspan="4" align="left">30</td>
<td rowspan="4" align="left">11,15-Di-(3-nitrobenzoyl)pseudokobusine</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">5.0 (GI<sub>50</sub>)</td>
<td rowspan="4" align="left">
<xref ref-type="bibr" rid="B112">Wada et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">DU145</td>
<td align="left">Prostate cancer</td>
<td align="left">5.2 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td align="left">KB</td>
<td align="left">Nasopharyngeal carcinoma</td>
<td align="left">5.6 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td align="left">KB-VIN</td>
<td align="left">Vincristine-resistant KB subline</td>
<td align="left">5.6 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td rowspan="4" align="left">31</td>
<td rowspan="4" align="left">11-(3-Trifluoromethylbenzoyl)pseudokobusine</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">6.8 (GI<sub>50</sub>)</td>
<td rowspan="4" align="left">
<xref ref-type="bibr" rid="B112">Wada et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">DU145</td>
<td align="left">Prostate cancer</td>
<td align="left">7.7 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td align="left">KB</td>
<td align="left">Nasopharyngeal carcinoma</td>
<td align="left">8.9 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td align="left">KB-VIN</td>
<td align="left">Vincristine-resistant KB subline</td>
<td align="left">6.2 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td rowspan="4" align="left">32</td>
<td rowspan="4" align="left">11-Tritylpseudokobusine</td>
<td align="left">A549</td>
<td align="left">Lung cancer</td>
<td align="left">6.4 (GI<sub>50</sub>)</td>
<td rowspan="4" align="left">
<xref ref-type="bibr" rid="B112">Wada et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">DU145</td>
<td align="left">Prostate cancer</td>
<td align="left">6.0 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td align="left">KB</td>
<td align="left">Nasopharyngeal carcinoma</td>
<td align="left">6.6 (GI<sub>50</sub>)</td>
</tr>
<tr>
<td align="left">KB-VIN</td>
<td align="left">Vincristine-resistant KB subline</td>
<td align="left">5.2 (GI<sub>50</sub>)</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-4">
<title>Non-Diterpenoid Alkaloids</title>
<p>Apart from C<sub>18</sub>, C<sub>19</sub>, and C<sub>20</sub> diterpenoid alkaloids, other types of alkaloids in Fuzi such as higenamine and salsolinol also manifested antitumor biological function. Higenamine enhanced the anticancer effects of cucurbitacin B in breast cancer by suppressing the interaction of protein kinase B (AKT) and cyclin-dependent kinase 2 (CDK2) (<xref ref-type="bibr" rid="B51">Jin et al., 2018</xref>). In colorectal cancer-bearing nude mice, higenamine inhibited tumor volume by inducing apoptosis (<xref ref-type="bibr" rid="B98">Song et al., 2020</xref>). Salsolinol, a water-soluble alkaloid in Fuzi, induced apoptosis of human neuroblastoma SH-SY5Y cells. After incubation with salsolinol, the levels of Bcl-2 decreased, while protein Bax and the release of cytochrome C increased, which led to mitochondrial dysfunction and apoptosis (<xref ref-type="bibr" rid="B116">Wanpen et al., 2007</xref>). <xref ref-type="fig" rid="F4">Figure 4</xref> displays the structures of higenamine and salsolinol.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Structures of higenamine and salsolinol in Fuzi.</p>
</caption>
<graphic xlink:href="fphar-13-870282-g004.tif"/>
</fig>
</sec>
</sec>
<sec id="s3">
<title>Fuzi Polysaccharides (FPS)</title>
<p>Polysaccharide is another key component of Fuzi, responsible for anti-inflammatory, anticancer, immunoregulatory, and cholesterol-lowering efficacies (<xref ref-type="bibr" rid="B67">Liu et al., 2019</xref>). FPS is mainly composed of glucose, galacturonic acid, galactose, arabinose, and mannose (<xref ref-type="bibr" rid="B70">Lu et al., 2011</xref>; <xref ref-type="bibr" rid="B124">Xu et al., 2014</xref>). One neutral FPS (FPS1) with 97% purity was isolated from Fuzi. FPS1 was composed of glucan as confirmed by acid hydrolysis, thin-layer chromatography, and infrared spectroscopy (<xref ref-type="bibr" rid="B90">Ruan et al., 2000</xref>). In addition, a water-soluble FPS (FPS2) was identified as a (1&#x2192;3)-branched &#x3b1;-(1&#x2192;6)-D-glucan. Through the study of structure&#x2013;activity relationship, it was found that &#x3b2;-glucans and &#x3b1;-glucans consisting of (1&#x2192;3)-glucopyranosyl units with (1&#x2192;6)-linked side chains could activate leukocytes, stimulate the phagocytosis, and potentiate host response against many diseases such as cancer and infection. Likewise, in FPS2, &#x3b1;-glucans with similar linkage patterns displayed immunostimulatory activities as well (<xref ref-type="bibr" rid="B131">Zhao et al., 2006</xref>)<bold>.</bold>
</p>
<p>So far, most studies considered that FPS exerted the antineoplastic effects indirectly by enhancing the immunity capacity. When FPS was used in combination with chemotherapeutic drugs, it exhibited synergism and increased potencies to promote the apoptosis of tumor cells (<xref ref-type="bibr" rid="B22">Dong et al., 2003a</xref>; <xref ref-type="bibr" rid="B23">Dong et al., 2003b</xref>; <xref ref-type="bibr" rid="B33">Gao et al., 2012b</xref>). FPS enhanced the anticancer activity of adriamycin long circulating liposome in treating liver cancer H22 mice by promoting lymphocyte proliferation and potentiating the cytotoxic index of natural killer (NK) cells (<xref ref-type="bibr" rid="B21">Dong et al., 2006</xref>). Furthermore, FPS prevented the proliferation and migration of tumor cells <italic>via</italic> restraining the synthesis of glycosyltransferase and matrix metalloproteinases (<xref ref-type="bibr" rid="B34">Gao et al., 2016</xref>; <xref ref-type="bibr" rid="B5">An et al., 2019</xref>).</p>
</sec>
<sec id="s4">
<title>Anticancer Mechanisms of Fuzi Alkaloids and Polysaccharides</title>
<sec id="s4-1">
<title>Induce Apoptosis and Autophagy</title>
<p>As we know, apoptosis is crucial to the development of the body and the stability of internal environment. When carcinogenic driving factors lead to excessive cell proliferation, it usually triggers apoptosis (<xref ref-type="bibr" rid="B37">Green and Evan, 2002</xref>). Apoptosis is also called programmed cell death. The process of apoptosis is actually a cascade amplification process of irreversible hydrolysis of substrate by cysteinyl aspartate specific proteinase (caspase) (<xref ref-type="bibr" rid="B77">McIlwain et al., 2015</xref>), which could be divided into two major categories (intrinsic pathway and extrinsic pathway) (<xref ref-type="bibr" rid="B13">Carneiro and El-Deiry, 2020</xref>). As a lysosome degradation pathway with the function of nutritional circulation and metabolic adaptation, autophagy is considered to be involved in the regulation of cancer (<xref ref-type="bibr" rid="B4">Amaravadi et al., 2019</xref>). In many cases, autophagy is closely related to apoptosis, and autophagy-related genes are also involved in the process of apoptosis (<xref ref-type="bibr" rid="B73">Maheswari et al., 2018</xref>). Inducing apoptosis and autophagy is one of the primary mechanisms responsible for the anticancer effect of Fuzi alkaloids and polysaccharides.</p>
<sec id="s4-1-1">
<title>Mitochondrial-Mediated Apoptosis</title>
<p>Mitochondria are the regulatory center of apoptosis. There is usually an increase in mitochondrial outer membrane permeability in the last step of apoptosis, accompanied by the release of cytochrome C (Cyto C) (<xref ref-type="bibr" rid="B50">Jin and El-Deiry, 2005</xref>; <xref ref-type="bibr" rid="B52">Kalkavan and Green, 2018</xref>). Mitochondrial-mediated apoptosis pathway (intrinsic pathway) is usually accompanied by changes in Bax, Bcl-2, Cyto C, ROS, caspase-3, etc. Bcl-2 and Bax are anti- and pro-apoptotic members of Bcl-2 family respectively, which could affect caspase cascade pathways in apoptosis. Cyto C is a key protein encoded by nuclear genes and its release is regulated by the members of Bcl-2 family (<xref ref-type="bibr" rid="B60">Li et al., 1997</xref>; <xref ref-type="bibr" rid="B15">Chao and Korsmeyer, 1998</xref>; <xref ref-type="bibr" rid="B76">Martinou and Youle, 2011</xref>). Aconitine promoted the release of Cyto C by directly increasing the production of reactive oxygen species (ROS) in mitochondria and ultimately induced cell apoptosis. This was demonstrated by the increased expression of caspase-3, caspase-7, Bax/Bcl-2, and PARP in HepG2 cells (<xref ref-type="bibr" rid="B85">Qi et al., 2018</xref>). Salsolinol (250 and 500&#xa0;&#x3bc;M) caused the release of mitochondrial Cyto C in human neuroblastoma SH-SY5Y cells. At the same time, increased levels of Bax and decreased Bcl-2 were detected by western blotting analysis (<xref ref-type="bibr" rid="B116">Wanpen et al., 2007</xref>). Moreover, salsolinol enhanced the activity of caspase-3 in a time-dependent manner in SH-SY5Y cells (<xref ref-type="bibr" rid="B48">Jantas et al., 2008</xref>). NF-&#x3ba;B is a downstream gene of tumor necrosis factor &#x3b1; (TNF-&#x3b1;) pathway and participates in cell apoptosis (<xref ref-type="bibr" rid="B18">Covert et al., 2005</xref>). Studies demonstrated that a series of processes, such as inflammation, angiogenesis, invasion, and cellular metabolism, were controlled by the NF-&#x3ba;B pathway (<xref ref-type="bibr" rid="B105">Taniguchi and Karin, 2018</xref>). The activation of the pathway was observed in most kinds of cancers (<xref ref-type="bibr" rid="B126">Yu et al., 2020</xref>). The NF-&#x3ba;B pathway was involved in the apoptosis induced by Fuzi alkaloids. With the increment of aconitine, the expression of NF-&#x3ba;B and Bcl-2 decreased gradually, while the protein levels of Bax, caspase-3, caspase-9, PARP, and Cyto C increased (<xref ref-type="bibr" rid="B49">Ji et al., 2016</xref>). The research indicated that inhibiting the NF-&#x3ba;B pathway initiated the apoptosis program. Therefore, NF-&#x3ba;B might serve as a promising target in cancer therapy.</p>
<p>Endoplasmic reticulum (ER) dysfunction is to blame for ER-dominated apoptosis to a large extent. In cells, protein synthesis, processing, and modification depend heavily on ER. However, under the condition of viral infection and pH imbalance, the accumulation and aggregation of unfolded proteins would cause severe ER stress (ERS) (<xref ref-type="bibr" rid="B46">Hu et al., 2019</xref>). The apoptosis induced by C/EBP homologous protein (CHOP) pathway is a critical manner of ERS-mediated apoptosis, which is mainly regulated by kinase and transcription factors such as PKR-like endoplasmic reticulum kinase (PERK), eukaryotic translation initiation factor 2&#x3b1; (eIF2&#x3b1;), activating transcription factor 6 (ATF6), inositol-requiring enzyme-1 (IRE1), and X-box binding protein 1 (XBP1) (<xref ref-type="bibr" rid="B82">Oyadomari and Mori, 2004</xref>; <xref ref-type="bibr" rid="B103">Tabas and Ron, 2011</xref>; <xref ref-type="bibr" rid="B91">Sanchez-Lopez et al., 2013</xref>). The triggering of CHOP pathway is closely associated with mitochondria-mediated apoptosis, including increasing the expression of Bim and decreasing the expression of Bcl-2 (<xref ref-type="bibr" rid="B46">Hu et al., 2019</xref>). It was found that aconitine and quercetin increased apoptosis in human cervical cancer HeLa cells. The two components synergistically activated the glucose-regulated protein 78 (GRP78), a maker of ERS, eventually inducing ERS-mediated apoptosis by upregulating the PERK/eIF2&#x3b1;/ATF4/CHOP pathway (<xref ref-type="bibr" rid="B61">Li et al., 2018</xref>).</p>
</sec>
<sec id="s4-1-2">
<title>Death Receptor-Mediated Apoptosis</title>
<p>Death receptors on cell membranes play a crucial role in apoptosis. They induce apoptosis by binding to relevant ligands and transmitting apoptotic signals that eventually cause tumor cell death. Accordingly, the death receptor-mediated pathways could be applied to the field of tumor therapy (<xref ref-type="bibr" rid="B125">Yang, 2020</xref>). Death receptors are the initial part of extrinsic apoptosis, including Fas, TNF-R1/TNF-R2, and DR4/DR5, etc. (<xref ref-type="bibr" rid="B69">Locksley et al., 2001</xref>; <xref ref-type="bibr" rid="B72">MacEwan, 2002</xref>; <xref ref-type="bibr" rid="B6">Ashkenazi and Salvesen, 2014</xref>). Exogenous death receptor-mediated pathway initiates apoptosis by activating Fas, TNF-R, and other receptors on the cell membrane. When the death receptor binds to its ligand, the apoptosis signal can be transmitted to adaptor protein such as FADD, and then FADD binds to the initial protein caspase-8 or caspase-10, promoting the release of Cyto C and further triggering the cascade of caspase proteolysis (<xref ref-type="bibr" rid="B56">Lavrik et al., 2005</xref>; <xref ref-type="bibr" rid="B7">Billen et al., 2008</xref>; <xref ref-type="bibr" rid="B115">Walczak, 2013</xref>). Aconitine upregulated the expression of DR5 and TNF-R1 by targeting the p38 MAPK, accordingly activating Bax in A549 cells in a concentration-dependent manner, revealing that aconitine exerted the anticancer effects through the death receptor-mediated apoptosis (<xref ref-type="bibr" rid="B25">Fan et al., 2016</xref>). Studies showed that <italic>p53</italic> gene could induce apoptosis, regulate cell cycle, and repair DNA damage (<xref ref-type="bibr" rid="B132">Zhao et al., 2021</xref>). It is noteworthy that <italic>p53</italic> could directly participate in the transcription and regulation of death receptors, such as Fas and DR5 (<xref ref-type="bibr" rid="B24">El-Deiry, 1998</xref>). Mesaconitine induced apoptosis of leukemia daunorubicin-resistant cells, whose mechanism might be related to the upregulation of <italic>p53</italic> and caspase-3 (<xref ref-type="bibr" rid="B38">Guan et al., 2017</xref>). S180 sarcoma and H22 liver cancer mice experiments showed that both crude and acidic FPS inhibited neoplasm tissues growth significantly. Further research revealed that the two FPS increased tumor cell apoptosis by upregulating the expression of <italic>p53</italic> and Fas (<xref ref-type="bibr" rid="B22">Dong et al., 2003a</xref>).</p>
</sec>
<sec id="s4-1-3">
<title>Autophagy</title>
<p>Autophagy is a defense and stress-regulation mechanism of the body, which is essential for maintaining cell homeostasis. Autophagy would be triggered in states of excessive hunger, nutritional deficiency, oxidative stress, etc. (<xref ref-type="bibr" rid="B3">Amaravadi et al., 2016</xref>). Beclin-1 is a critical regulator of autophagy, which mainly participates in the formation of autophagosomes and could be blocked by Bcl-2 (<xref ref-type="bibr" rid="B74">Mari&#xf1;o et al., 2014</xref>). Studies indicated that oncogenic proteins inhibited the occurrence of autophagy. On the contrary, oncosuppressor proteins could activate autophagy (<xref ref-type="bibr" rid="B31">Galluzzi et al., 2015</xref>). The process of autophagy was initiated by the phosphorylated <italic>Beclin-1</italic> gene, and then gene <italic>LC3</italic> would be transformed into the membrane type <italic>LC3-II</italic>, eventually substrate p62 protein would be degraded (<xref ref-type="bibr" rid="B81">Onorati et al., 2018</xref>; <xref ref-type="bibr" rid="B59">Levine and Kroemer, 2019</xref>). It was reported that benzoylaconitine induced autophagy and apoptosis of human lung cancer A549 cells by upregulating Beclin-1, LC3-&#x2161;, Bax, and caspase-3, meanwhile downregulating p62 and Bcl-2 (<xref ref-type="bibr" rid="B92">Shao et al., 2019</xref>). The results suggested that Fuzi alkaloids could promote the expression of autophagy and pro-apoptotic-related proteins, also inhibit the anti-apoptotic protein such as Bcl-2 to conduct autophagy and apoptosis.</p>
</sec>
</sec>
<sec id="s4-2">
<title>Inhibit Proliferation, Migration, and Invasion</title>
<p>Proliferation, migration, and invasion are basic biological characteristics of malignancies. Uncontrolled proliferation, rapid migration, and excessive invasion of tumor cells are leading causes for poor prognosis and high recurrence. Accordingly, inhibition of these pathological processes would contribute to the anticancer efficacies of Fuzi. Studies have demonstrated that several processes and targets were involved in these pathological processes, including p38 MAPK, AKT, EMT, &#x3b2;3GnT8, and MMPs.</p>
<sec id="s4-2-1">
<title>p38 MAPK</title>
<p>Mitogen-activated protein kinase (MAPK), composed of three kinase members, p38 MAPK, ERK, and JNK, could be activated by a variety of mitogens and sequentially induced cells enter into the division cycle. Researches revealed that p38 MAPK pathway took part in the regulation of cell proliferation, migration, and apoptosis (<xref ref-type="bibr" rid="B75">Mart&#xed;nez-Lim&#xf3;n et al., 2020</xref>). MAPKAPK, a downstream target of p38 MAPK, directly induced phosphorylation of heat shock protein 27 (HSP27) and regulated cell migration, proliferation and apoptosis. Evidence was provided that p38 MAPK played a pivotal part in the occurrence and progression of cancer. Aconitine could significantly reduce the phosphorylation of p38, MAPKAPK, and HSP27 in liver cancer cells, indicating that aconitine suppressed the proliferation of MHCC97 cells by restraining the activation of p38 MAPK pathway (<xref ref-type="bibr" rid="B123">Xiong et al., 2018</xref>).</p>
</sec>
<sec id="s4-2-2">
<title>AKT</title>
<p>AKT, a serine/threonine kinase, is involved in cell growth, proliferation, apoptosis, survival, and glycogen metabolism (<xref ref-type="bibr" rid="B20">Datta et al., 1999</xref>). As an oncogenic protein, the activation of AKT is a general molecular biological feature in cancer (<xref ref-type="bibr" rid="B44">Hennessy et al., 2005</xref>; <xref ref-type="bibr" rid="B93">Shaw and Cantley, 2006</xref>; <xref ref-type="bibr" rid="B97">Song et al., 2019</xref>). Studies found that higenamine combined with cucurbitacin B blocked breast cancer cells in the G<sub>2</sub>/M phase. Furthermore, combination of the two ingredients decreased the expression of AKT and cell-cycle-related protein CDK2, indicating that higenamine possibly suppressed the proliferation of tumor cells by regulating the AKT signaling pathway negatively (<xref ref-type="bibr" rid="B51">Jin et al., 2018</xref>).</p>
</sec>
<sec id="s4-2-3">
<title>EMT</title>
<p>Epithelial&#x2013;mesenchymal transition (EMT) refers to a biological process of epithelial cells transforming into cells with mesenchymal phenotype by specific procedures, which is linked to tumor invasion and migration. EMT is related to many mediators, such as transforming growth factor-&#x3b2;1 (TGF-&#x3b2;1), snail homolog 1 (Snail), and NF-&#x3ba;B pathways (<xref ref-type="bibr" rid="B28">Feng et al., 2020</xref>). Hypaconitine could significantly suppress TGF-&#x3b2;1-induced EMT in lung cancer A549 cells. Further investigation verified that hypaconitine attenuated nuclear translocation of NF-&#x3ba;B and reduced the expression of Snail, which showed a similar inhibitory effect on the NF-&#x3ba;B inhibitor. In the meantime, a significant decrease was observed in cell adhesion, invasion, and migration (<xref ref-type="bibr" rid="B27">Feng et al., 2017</xref>). The results suggested that hypoaconitine showed its anticancer potential via suppressing EMT.</p>
</sec>
<sec id="s4-2-4">
<title>&#x3b2;3GnT8</title>
<p>Studies observed that the aberrant glycosylation on the surface of tumor cells is a common feature of tumor malignant transformation and metastasis, which usually involves the modifications of terminal sialylation, fucosylation, O-glycan truncation, etc. (<xref ref-type="bibr" rid="B10">Bresalier et al., 1998</xref>; <xref ref-type="bibr" rid="B83">Pinho and Reis, 2015</xref>; <xref ref-type="bibr" rid="B12">Cagnoni et al., 2016</xref>; <xref ref-type="bibr" rid="B35">Girotti et al., 2020</xref>). Deregulation of glycosyltransferase in tumor cells leads to an altered glycan pattern of numerous proteins, resulting in abnormal glycosylation of proteins, and ultimately leading to the dysfunction of proteins, which might be involved in the metastasis of tumor cells (<xref ref-type="bibr" rid="B80">Oliveira-Ferrer et al., 2017</xref>). &#x3b2;1, 3-N-acetylglucosminyltransferase 8 (&#x3b2;3GnT8) is a glycosyltransferase that could catalyze the synthesis of polylactosamine chains and promote cell glycosylation. The polylactosamine chains and their related structures participated in the invasion and migration of tumor cells (<xref ref-type="bibr" rid="B65">Liu, 2017</xref>). It was found that FPS directly targeted the &#x3b2;3GnT8. The malignancy of tumor-bearing mice decreased along with a reduced expression of &#x3b2;3GnT8 and polylactosamine in liver cancer SK-HEP-1 cells after treatment with FPS, indicating that FPS inhibited the migration and invasion through downregulating &#x3b2;3GnT8 (<xref ref-type="bibr" rid="B34">Gao et al., 2016</xref>).</p>
</sec>
<sec id="s4-2-5">
<title>MMPs</title>
<p>Members of matrix metalloproteinases (MMPs) family mainly catalyze the proteolytic activities and thereby aid the breakdown of extracellular matrix (ECM), which is a vital tissue barrier for tumor metastasis (<xref ref-type="bibr" rid="B107">Vandenbroucke and Libert, 2014</xref>). MMPs are upregulated through all stages of cancer that could degrade various proteins in ECM and destroy the histological barrier against cell invasion (<xref ref-type="bibr" rid="B47">Isaacson et al., 2017</xref>). To date, 23 MMP family members have been found in humans. Numerous studies focus on the design of targeted antineoplastic agents by inhibiting MMPs (<xref ref-type="bibr" rid="B14">Cathcart et al., 2015</xref>; <xref ref-type="bibr" rid="B19">Das et al., 2021</xref>). MMP-2 and MMP-14, two members in the MMPs family, could degrade ECM, promote vascular proliferation, enhance cell migration and invasion, and are considered potential biomarkers of certain cancers (<xref ref-type="bibr" rid="B2">Alaseem et al., 2019</xref>; <xref ref-type="bibr" rid="B53">Karamanou et al., 2020</xref>). FPS reduced the tumor weight and blocked the expression of MMP-2 and MMP-14 in mice transplanted with gastric cancer, suggesting that FPS exerted anticancer effect by downregulating MMP-2 and MMP-14 (<xref ref-type="bibr" rid="B5">An et al., 2019</xref>).</p>
<p>The involved mechanisms of inducing apoptosis and autophagy, inhibiting cell proliferation, migration, and invasion through different molecular pathways by Fuzi alkaloids and FPS are illustrated in <xref ref-type="fig" rid="F5">Figure 5</xref>.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>The molecular mechanisms of Fuzi against cancer. 1) Fuzi induced cell autophagy and conducted apoptosis by targeting mitochondrial-mediated pathway and death receptor-mediated pathway. 2) Fuzi inhibited cell proliferation, migration, and invasion via regulating p38 MAPK, AKT, EMT, &#x3b2;3GnT8 and MMPs. The blue and brown solid arrows indicated direct targets of Fuzi alkaloids and FPS respectively. Correspondingly, the blue and brown dotted ones indicated downstream effects induced by Fuzi alkaloids and FPS.</p>
</caption>
<graphic xlink:href="fphar-13-870282-g005.tif"/>
</fig>
</sec>
</sec>
<sec id="s4-3">
<title>Regulate Immunity</title>
<p>The immune escape of tumor refers to the phenomenon that tumor cells escape the recognition and attack of immune system through a variety of mechanisms, so as to survive and proliferate in the body. Some cytokines, such as interleukin-2 (IL-2), IL-6, and IL-12, are able to enhance immune response. In contrast, regulatory T cells (Tregs) could rapidly detect and inhibit IL-2 or other cytokines in the early stage of the immune response to suppress autoimmunity, which might hinder the anticancer immunity (<xref ref-type="bibr" rid="B119">Wing et al., 2019</xref>). Therefore, inhibiting the production of Tregs is one of the methods of anticancer immunotherapy. Fuzi aqueous extract has been proved to enhance the anticancer effect of radiotherapy in the treatment of lung cancer. The experimental data indicated that ionizing radiation affected the anticancer immune response of mice. However, after the administration of Fuzi aqueous extract, the levels of IL-2, IL-6, and IL-12 in mice serum increased, which might arouse the immune response. Moreover, Fuzi aqueous extract reduced the radiation-induced production of IL-10, TGF-&#x3b2;, and Tregs, revealing the mechanism of Fuzi in modulating immunity and inhibiting tumor growth (<xref ref-type="bibr" rid="B128">Zhang et al., 2017</xref>). Another research showed that, in gastric cancer-bearing mice, aconitine was involved in the intervention of Tregs by regulating the prostaglandin E2/cyclooxygenase-2 (PGE2/COX-2) pathway. It was noteworthy that high-dose aconitine reduced PGE2 and Tregs significantly, whose effect was more obvious than that of the celecoxib-positive group. These results suggested that aconitine exerted antitumor efficacy by reversing immune escape through regulating Tregs and mediating the PGE2/COX-2 pathway (<xref ref-type="bibr" rid="B16">Cheng, 2019</xref>).</p>
<p>Cancer immunotherapy aims to promote tumor-specific T-cell response. As antigen-presenting cells, dendritic cells (DC) allow antigens to be recognized by CD4<sup>&#x2b;</sup> T cells and CD8<sup>&#x2b;</sup> T cells, and then CD4<sup>&#x2b;</sup> T cells transmit information to CD8<sup>&#x2b;</sup> T cells and facilitate the differentiation of effector T cells to kill tumor cells (<xref ref-type="bibr" rid="B8">Borst et al., 2018</xref>). Aconitine possessed a direct anticancer activity, but it also had the drawback of damaging immunity to a certain extent (<xref ref-type="bibr" rid="B86">Qian, 2015</xref>). FPS increased the number of macrophages, CD4<sup>&#x2b;</sup>, and CD8<sup>&#x2b;</sup> T cells in the spleen of Hepa1-6 tumor-bearing mice, indicating FPS had immune-improving functions. The results suggested that FPS combined with Fuzi alkaloids might achieve better anticancer efficacy (<xref ref-type="bibr" rid="B86">Qian, 2015</xref>). Treatment with FPS induced differentiation of peripheral blood monocytes to DC and expressed its mature phenotypes, which acted as the second signal to activate T lymphocytes and stimulated tumor immunity (<xref ref-type="bibr" rid="B33">Gao L. L. et al., 2012</xref>). The synergic effect of FPS and adriamycin was evaluated in H22 tumor-bearing mice. The killing activity of NK cells and lymphocyte transformation rate were dramatically improved; meanwhile the expression of IL-2 and IL-12 in splenic lymphocytes increased, indicating that FPS enhanced the anticancer effect of adriamycin by strengthening the immune system (<xref ref-type="bibr" rid="B23">Dong et al., 2003b</xref>; <xref ref-type="bibr" rid="B21">Dong et al., 2006</xref>). The anticancer immunomodulatory mechanism of Fuzi is shown in <xref ref-type="fig" rid="F6">Figure 6</xref>.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>The anticancer immunomodulatory mechanism of Fuzi. Fuzi induced peripheral blood monocytes to differentiate into DC, activated T lymphocytes, and increased the expression of macrophages, CD4<sup>&#x2b;</sup>, CD8<sup>&#x2b;</sup> T cells, NK cells, IL2, IL-12, IL-6, etc. Besides, Fuzi reduced the production of IL-10, TGF-&#x3b2;, Treg, and arrested PGE2/COX-2 pathway. The blue, brown and green dotted arrows indicated the influence induced by alkaloids, FPS and Fuzi aqueous extract respectively.</p>
</caption>
<graphic xlink:href="fphar-13-870282-g006.tif"/>
</fig>
</sec>
<sec id="s4-4">
<title>Affect Energy Metabolism</title>
<p>The abnormal energy metabolism is one of the major characteristics of tumor cells (<xref ref-type="bibr" rid="B40">Hanahan and Weinberg, 2011</xref>). The main sources of biological energy depend on central carbon metabolism, including aerobic respiration and glycolysis. In the presence of adequate oxygen, pyruvate, transformed from glucose, is further oxidatively phosphorylated by mitochondrial respiration. However, under hypoxic conditions, pyruvate would be reduced to lactate. Tumor cells tend to obtain ATP through glycolysis even under aerobic conditions, this phenomenon is called Warburg effect (<xref ref-type="bibr" rid="B117">Warburg et al., 1927</xref>). PI3K/AKT/mTOR and HIF-1 pathways would influence glycolysis and participate in the energy metabolism of tumor cells. The PI3K/AKT/mTOR pathway could activate glucose transporters on cell membrane and the metabolic enzyme hexokinase 2 (HK2) in glycolysis, sequentially increase glucose uptake and glycolysis rate (<xref ref-type="bibr" rid="B36">Gottlob et al., 2001</xref>; <xref ref-type="bibr" rid="B89">Roberts et al., 2013</xref>; <xref ref-type="bibr" rid="B1">Abdel-Wahab et al., 2019</xref>). The HIF-1&#x3b1; could induce the activation of lactate dehydrogenase A (LDHA) and pyruvate dehydrogenase kinase 1 (PDK1) to catalyze the conversion of pyruvate to lactate, accordingly promote glycolysis to produce ATP in the anoxic tumor microenvironment (<xref ref-type="bibr" rid="B106">Valvona et al., 2016</xref>; <xref ref-type="bibr" rid="B133">Zhou et al., 2018</xref>; <xref ref-type="bibr" rid="B79">Nagao et al., 2019</xref>).</p>
<p>Mitochondria are the most important organelle of energy metabolism. Besides supplying energy for life, mitochondria also regulate cell death, control redox reactions, and provide substrates for anabolism (<xref ref-type="bibr" rid="B84">Porporato et al., 2018</xref>). Angiogenesis in the center of many solid tumors is poor, resulting in limited supply of glucose and oxygen. However, electron transport chain (ETC) in the mitochondria could function even under hypoxia, allowing the tumor cells to breathe and produce ATP (<xref ref-type="bibr" rid="B108">Vasan et al., 2020</xref>). Complex I, II, III, and IV, located on the mitochondrial inner membrane, are key components of ETC to transfer electrons. Complex I and II respectively oxidize the NADH and FADH<sub>2</sub> to NAD<sup>&#x2b;</sup> (nicotinamide adenine dinucleotide) and FAD<sup>&#x2b;</sup> (flavin adenine dinucleotide), which keep TCA cycle running. Complex I, II, III, and IV transfer electrons to oxygen, discharge protons into the gap of mitochondrial membrane, and eventually generate ATP by ATP synthase (<xref ref-type="bibr" rid="B58">Letts and Sazanov, 2017</xref>). Regulation of cellular metabolism might be a significant clue in developing antineoplastic agents (<xref ref-type="bibr" rid="B100">Stuart et al., 2014</xref>; <xref ref-type="bibr" rid="B118">Wheaton et al., 2014</xref>; <xref ref-type="bibr" rid="B55">Kuntz et al., 2017</xref>). <xref ref-type="fig" rid="F7">Figure 7</xref> shows glycolysis, TCA cycle, and relevant pathways involved in cellular energy metabolism.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>The influence of Fuzi alkaloids on cancer energy metabolism. Fuzi regulated the energy supply of cancer cells, as well as induced cell death by inhibiting mitochondrial complex II, PI3K/AKT/mTOR pathway, HIF-1 pathway, and central carbon metabolism. The blue dotted arrow indicated the effect induced by Fuzi alkaloids.</p>
</caption>
<graphic xlink:href="fphar-13-870282-g007.tif"/>
</fig>
<p>Existing studies found that Fuzi alkaloids regulated cellular metabolism by affecting ETC in the mitochondria. Salsolinol blocked the energy supply of SH-SY5Y cells and induced cell death. It was noteworthy that adding <sc>d</sc>-glucose to enhance glycolysis could not prevent the cytotoxicity of salsolinol on SH-SY5Y cells. Further research demonstrated that salsolinol inhibited the activity of complex II (succinate-Q reductase) and caused a rapid depletion in intracellular ATP, which might account for the cytotoxic effects of salsolinol (<xref ref-type="bibr" rid="B99">Storch et al., 2000</xref>). Moreover, network pharmacology predicted that Fuzi alkaloids might exert antitumor effects by suppressing the PI3K/AKT/mTOR pathway, HIF-1 pathway, and central carbon metabolism in cancer (<xref ref-type="bibr" rid="B71">Lu et al., 2021</xref>) (<xref ref-type="fig" rid="F7">Figure 7</xref>). The evidence proved that energy metabolism and its relevant signal pathways might be involved in the anticancer process of Fuzi alkaloids.</p>
</sec>
<sec id="s4-5">
<title>Reverse Multidrug Resistance</title>
<p>Multidrug resistance (MDR) is a principal reason of the therapeutic failure. P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) located on the cell membrane control the absorption, distribution, and excretion of various chemicals. These transporters protect cancer cells from high doses of intracellular drugs and lead to the occurrence of MDR (<xref ref-type="bibr" rid="B11">Bukowski et al., 2020</xref>). Many inhibitors, such as verapamil and cyclosporine A, are designed to target P-gp. However, due to the low affinity of these inhibitors to P-gp, high concentrations are required and side effects would ensue (<xref ref-type="bibr" rid="B45">H&#xf6;llt et al., 1992</xref>; <xref ref-type="bibr" rid="B64">List et al., 2001</xref>; <xref ref-type="bibr" rid="B114">Waghray and Zhang, 2018</xref>). Aconitine was shown to reverse the MDR of KB<sub>V200</sub> cells, accordingly the inhibitory rate by aconitine reached 56.15% at 50&#xa0;&#x3bc;g/ml. The combined use of aconitine and vincristine achieved a better reversal effect of MDR, largely due to downregulating P-gp expression (<xref ref-type="bibr" rid="B66">Liu et al., 2004</xref>).</p>
<p>The anticancer active compounds of Fuzi and their mechanisms are summarized in <xref ref-type="table" rid="T4">Table 4</xref>.</p>
<table-wrap id="T4" position="float">
<label>TABLE 4</label>
<caption>
<p>Anticancer constituents of Fuzi and relevant mechanisms.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Constituent</th>
<th align="center">Cells or cancer models</th>
<th align="center">Molecular mechanisms</th>
<th align="center">Reference</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td colspan="4" align="left">
<italic>
<bold>Induce apoptosis and autophagy</bold>
</italic>
</td>
</tr>
<tr>
<td align="left">&#x2003;Aconitine</td>
<td align="left">HepG2 cells</td>
<td align="left">Upregulated the expression of cleaved PARP, caspase-3, caspase-7, and Bax and downregulated the expression of Bcl-2</td>
<td align="left">
<xref ref-type="bibr" rid="B85">Qi et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">&#x2003;Salsolinol</td>
<td align="left">SH-SY5Y cells</td>
<td align="left">Upregulated the expression of Cyto C and Bax and downregulated the expression of Bcl-2</td>
<td align="left">
<xref ref-type="bibr" rid="B116">Wanpen et al. (2007)</xref>
</td>
</tr>
<tr>
<td align="left">&#x2003;Salsolinol</td>
<td align="left">SH-SY5Y cells</td>
<td align="left">Increased the release of caspase-3</td>
<td align="left">
<xref ref-type="bibr" rid="B48">Jantas et al. (2008)</xref>
</td>
</tr>
<tr>
<td align="left">&#x2003;Aconitine</td>
<td align="left">A549 cells</td>
<td align="left">Increased the expression of p38 MAPK, DR5, and TNF-R1</td>
<td align="left">
<xref ref-type="bibr" rid="B25">Fan et al. (2016)</xref>
</td>
</tr>
<tr>
<td align="left">&#x2003;Mesaconitine</td>
<td align="left">K562, K562 daunorubicin-resistant cells</td>
<td align="left">Increased the expression of caspase-3 and p53 to trigger death receptor-mediated apoptosis</td>
<td align="left">
<xref ref-type="bibr" rid="B38">Guan et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="left">&#x2003;FPS</td>
<td align="left">S180, H22 tumor-bearing mice</td>
<td align="left">Increased the expression of p53 and Fas</td>
<td align="left">
<xref ref-type="bibr" rid="B22">Dong et al. (2003a)</xref>
</td>
</tr>
<tr>
<td align="left">&#x2003;Aconitine</td>
<td align="left">HeLa cells</td>
<td align="left">Increased the expression of eIF2&#x3b1;, ATF4, IRE1, XBP1, ATF6, PERK, and CHOP</td>
<td align="left">
<xref ref-type="bibr" rid="B61">Li et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">&#x2003;Benzoylaconitine</td>
<td align="left">A549 cells</td>
<td align="left">Upregulated the expression of Beclin1, LC3-&#x2161;, Bax, and caspase-3 and downregulated the expression of p62 and Bcl-2</td>
<td align="left">
<xref ref-type="bibr" rid="B92">Shao et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">&#x2003;Aconitine</td>
<td align="left">Miacapa-2, PANC-1 cells</td>
<td align="left">Upregulated the expression of Bax, caspase-9, caspase-3, PARP, and Cyto C and downregulated the expression of Bcl-2 and NF- &#x3ba;B</td>
<td align="left">
<xref ref-type="bibr" rid="B49">Ji et al. (2016)</xref>
</td>
</tr>
<tr>
<td colspan="4" align="left">
<bold>
<italic>Inhibit proliferation, migration, and invasion</italic>
</bold>
</td>
</tr>
<tr>
<td align="left">&#x2003;Aconitine</td>
<td align="left">MHCC97 cells</td>
<td align="left">Inhibited the P38 MAPK pathway by suppressing the phosphorylation of p38, MAPKAPK, and HSP27</td>
<td align="left">
<xref ref-type="bibr" rid="B123">Xiong et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">&#x2003;Higenamine</td>
<td align="left">SKBr3, T47D cells</td>
<td align="left">Decreased the expression of p-AKT and p-CDK2</td>
<td align="left">
<xref ref-type="bibr" rid="B51">Jin et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">&#x2003;Hypaconitine</td>
<td align="left">A549 cells</td>
<td align="left">Suppressed EMT by reducing the expression of Snail and NF-&#x3ba;B</td>
<td align="left">
<xref ref-type="bibr" rid="B27">Feng et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="left">&#x2003;FPS</td>
<td align="left">SK-HEP-1 cells</td>
<td align="left">Downregulated the expression of &#x3b2;3GnT8 and polylactosamine</td>
<td align="left">
<xref ref-type="bibr" rid="B34">Gao et al. (2016)</xref>
</td>
</tr>
<tr>
<td align="left">&#x2003;FPS</td>
<td align="left">Gastric cancer xenografts in nude mice</td>
<td align="left">Suppressed the expression of MMP-2 and MMP-14</td>
<td align="left">
<xref ref-type="bibr" rid="B5">An et al. (2019)</xref>
</td>
</tr>
<tr>
<td colspan="4" align="left">
<bold>
<italic>Regulate immunity</italic>
</bold>
</td>
</tr>
<tr>
<td align="left">&#x2003;Fuzi aqueous extract</td>
<td align="left">Lewis cells</td>
<td align="left">Increased the release of IL-2, IL-5, IL-6, and IL-12 and decreased the release of IL-10, TGF-&#x3b2;, and Tregs</td>
<td align="left">
<xref ref-type="bibr" rid="B128">Zhang et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="left">&#x2003;Aconitine</td>
<td align="left">MFC tumor-bearing mice</td>
<td align="left">Downregulated the expression of PGE2 and Tregs</td>
<td align="left">
<xref ref-type="bibr" rid="B16">Cheng (2019)</xref>
</td>
</tr>
<tr>
<td align="left">&#x2003;FPS</td>
<td align="left">Hepa1-6 tumor-bearing mice</td>
<td align="left">Increased the number of macrophages and CD4<sup>&#x2b;</sup> and CD8<sup>&#x2b;</sup> T cells in spleen</td>
<td align="left">
<xref ref-type="bibr" rid="B86">Qian (2015)</xref>
</td>
</tr>
<tr>
<td align="left">&#x2003;FPS</td>
<td align="left">Peripheral blood monocytes</td>
<td align="left">Induced differentiation of peripheral blood monocytes to DC</td>
<td align="left">
<xref ref-type="bibr" rid="B33">Gao et al. (2012b)</xref>
</td>
</tr>
<tr>
<td align="left">&#x2003;FPS</td>
<td align="left">S-180, H22 tumor-bearing mice</td>
<td align="left">Increased the killing activity of NK cells, the transformation rate of T cells, and the expression of IL-2 and IL-12</td>
<td align="left">
<xref ref-type="bibr" rid="B23">Dong et al. (2003b)</xref>; <xref ref-type="bibr" rid="B21">Dong et al. (2006)</xref>
</td>
</tr>
<tr>
<td colspan="4" align="left">
<bold>
<italic>Affect energy metabolism</italic>
</bold>
</td>
</tr>
<tr>
<td align="left">&#x2003;Salsolinol</td>
<td align="left">SH-SY5Y cells</td>
<td align="left">Suppressed the activity of succinate-Q reductase</td>
<td align="left">
<xref ref-type="bibr" rid="B99">Storch et al. (2000)</xref>
</td>
</tr>
<tr>
<td colspan="4" align="left">
<bold>
<italic>Reverse multidrug resistance</italic>
</bold>
</td>
</tr>
<tr>
<td align="left">&#x2003;Aconitine</td>
<td align="left">KB<sub>V200</sub> cells</td>
<td align="left">Downregulated the expression of P-gp</td>
<td align="left">
<xref ref-type="bibr" rid="B66">Liu et al. (2004)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</sec>
<sec sec-type="conclusion" id="s5">
<title>Conclusion</title>
<p>Natural plants have attracted significant interest ascribed to their anticancer properties. In this review, we rounded up the available evidence on the antineoplastic efficacies of Fuzi. As mentioned above, Fuzi alkaloids and polysaccharides showed tumor-suppressive effects <italic>in vitro</italic> and <italic>in vivo</italic> by inducing apoptosis and autophagy, inhibiting cell proliferation, migration and invasion, regulating immunity, affecting energy metabolism, and reversing MDR. Several signaling pathways and biological processes were involved in these pharmacological functions, such as NF-&#x3ba;B, EMT, HIF-1, p38 MAPK, PI3K/AKT/mTOR, and TCA cycle. The anticancer molecular mechanism of Fuzi alkaloids and polysaccharides concluded in this review could lay a foundation for further basic research and clinical application.</p>
<p>Outstanding achievements have been obtained in the anticancer chemical elements and pharmacological mechanism of Fuzi. Nevertheless, there are some deficiencies in current research. Nowadays, researchers focus on alkaloid monomers, crude polysaccharide or Fuzi extract. Other constituents such as flavonoids, ceramides and fatty acids are seldomly investigated about their anticancer activity. According to the characteristics of multi-components and multi-targets of TCM, the combination efficacy and network regulation mechanism of bioactive constituents in Fuzi remain to be further studied. With the applications of diversified techniques, specific mechanisms such as drug ligand-receptor interactions and conformational changes of targets are expected to be clarified. To sum up, Fuzi and its active ingredients would serve as attractive therapeutic candidates for the development of anticancer drugs.</p>
</sec>
</body>
<back>
<sec id="s6">
<title>Author Contributions</title>
<p>WZ conceived and designed the manuscript. CL and WZ wrote the manuscript. LD and SC assisted with the manuscript preparation. LD, JS and YF revised and polished the manuscript. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s7">
<title>Funding</title>
<p>This work was supported by the National Natural Science Foundation of China (82104688), Natural Science Foundation of Jiangsu Province (BK20190800), Natural Science Foundation of the Jiangsu Higher Education Institutions of China (19KJB360004), and Natural Science Foundation of Nanjing University of Chinese Medicine (XPT82104688).</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s9">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdel-Wahab</surname>
<given-names>A. F.</given-names>
</name>
<name>
<surname>Mahmoud</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Al-Harizy</surname>
<given-names>R. M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Targeting Glucose Metabolism to Suppress Cancer Progression: Prospective of Anti-glycolytic Cancer Therapy</article-title>. <source>Pharmacol. Res.</source> <volume>150</volume>, <fpage>104511</fpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2019.104511</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alaseem</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alhazzani</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Dondapati</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Alobid</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bishayee</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rathinavelu</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Matrix Metalloproteinases: A Challenging Paradigm of Cancer Management</article-title>. <source>Semin. Cancer Biol.</source> <volume>56</volume>, <fpage>100</fpage>&#x2013;<lpage>115</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcancer.2017.11.008</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amaravadi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kimmelman</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>White</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Recent Insights into the Function of Autophagy in Cancer</article-title>. <source>Genes Dev.</source> <volume>30</volume> (<issue>17</issue>), <fpage>1913</fpage>&#x2013;<lpage>1930</lpage>. <pub-id pub-id-type="doi">10.1101/gad.287524.116</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amaravadi</surname>
<given-names>R. K.</given-names>
</name>
<name>
<surname>Kimmelman</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Debnath</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Targeting Autophagy in Cancer: Recent Advances and Future Directions</article-title>. <source>Cancer Discov.</source> <volume>9</volume> (<issue>9</issue>), <fpage>1167</fpage>&#x2013;<lpage>1181</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-19-0292</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>An</surname>
<given-names>Z. X.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y. L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y. J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Effect of Aconiti Lateralis Radix Praeparata Polysaccharide on Expressions of MMP-2, MMP-14 in Gastric Cancer Xenografts in Nude Mice</article-title>. <source>Chin. J. Exp. Traditional Med. Formulae</source> <volume>25</volume> (<issue>23</issue>), <fpage>79</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.13422/j.cnki.syfjx.20191621</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashkenazi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Salvesen</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Regulated Cell Death: Signaling and Mechanisms</article-title>. <source>Annu. Rev. Cel Dev Biol</source> <volume>30</volume>, <fpage>337</fpage>&#x2013;<lpage>356</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-cellbio-100913-013226</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Billen</surname>
<given-names>L. P.</given-names>
</name>
<name>
<surname>Shamas-Din</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Andrews</surname>
<given-names>D. W.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Bid: a Bax-like BH3 Protein</article-title>. <source>Oncogene</source> <volume>27</volume> (<issue>Suppl. 1</issue>), <fpage>S93</fpage>&#x2013;<lpage>S104</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2009.47</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borst</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ahrends</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>B&#x105;ba&#x142;a</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Melief</surname>
<given-names>C. J. M.</given-names>
</name>
<name>
<surname>Kastenm&#xfc;ller</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>CD4&#x2b; T Cell Help in Cancer Immunology and Immunotherapy</article-title>. <source>Nat. Rev. Immunol.</source> <volume>18</volume> (<issue>10</issue>), <fpage>635</fpage>&#x2013;<lpage>647</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-018-0044-0</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bray</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ferlay</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Soerjomataram</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Siegel</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Torre</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Jemal</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title>. <source>CA Cancer J. Clin.</source> <volume>68</volume> (<issue>6</issue>), <fpage>394</fpage>&#x2013;<lpage>424</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21492</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bresalier</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Mazurek</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sternberg</surname>
<given-names>L. R.</given-names>
</name>
<name>
<surname>Byrd</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Yunker</surname>
<given-names>C. K.</given-names>
</name>
<name>
<surname>Nangia-Makker</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>1998</year>). <article-title>Metastasis of Human colon Cancer Is Altered by Modifying Expression of the Beta-Galactoside-Binding Protein Galectin 3</article-title>. <source>Gastroenterology</source> <volume>115</volume> (<issue>2</issue>), <fpage>287</fpage>&#x2013;<lpage>296</lpage>. <pub-id pub-id-type="doi">10.1016/s0016-5085(98)70195-7</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bukowski</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kciuk</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kontek</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Mechanisms of Multidrug Resistance in Cancer Chemotherapy</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume> (<issue>9</issue>), <fpage>3233</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21093233</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cagnoni</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>P&#xe9;rez S&#xe1;ez</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Rabinovich</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>Mari&#xf1;o</surname>
<given-names>K. V.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Turning-Off Signaling by Siglecs, Selectins, and Galectins: Chemical Inhibition of Glycan-dependent Interactions in Cancer</article-title>. <source>Front. Oncol.</source> <volume>6</volume>, <fpage>109</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2016.00109</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carneiro</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>El-Deiry</surname>
<given-names>W. S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Targeting Apoptosis in Cancer Therapy</article-title>. <source>Nat. Rev. Clin. Oncol.</source> <volume>17</volume> (<issue>7</issue>), <fpage>395</fpage>&#x2013;<lpage>417</lpage>. <pub-id pub-id-type="doi">10.1038/s41571-020-0341-y</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cathcart</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pulkoski-Gross</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Targeting Matrix Metalloproteinases in Cancer: Bringing New Life to Old Ideas</article-title>. <source>Genes Dis.</source> <volume>2</volume> (<issue>`1</issue>), <fpage>26</fpage>&#x2013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.gendis.2014.12.002</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chao</surname>
<given-names>D. T.</given-names>
</name>
<name>
<surname>Korsmeyer</surname>
<given-names>S. J.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>BCL-2 Family: Regulators of Cell Death</article-title>. <source>Annu. Rev. Immunol.</source> <volume>16</volume>, <fpage>395</fpage>&#x2013;<lpage>419</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.immunol.16.1.395</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2019</year>). <source>Intervention of Aconitine on Treg in Gastric Cancer-Bearing Mice by Regulating PGE2/COX2 Pathway</source>. <comment>Master&#x2019;s thesis</comment>. <publisher-loc>Hefei</publisher-loc>: <publisher-name>Anhui University of Chinese Medicine</publisher-name>. </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chodoeva</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bosc</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Guillon</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Decendit</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Petraud</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Absalon</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>8-O-Azeloyl-14-benzoylaconine: A New Alkaloid from the Roots of Aconitum Karacolicum Rapcs and its Antiproliferative Activities</article-title>. <source>Bioorg. Med. Chem.</source> <volume>13</volume> (<issue>23</issue>), <fpage>6493</fpage>&#x2013;<lpage>6501</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2005.07.015</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Covert</surname>
<given-names>M. W.</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>T. H.</given-names>
</name>
<name>
<surname>Gaston</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Baltimore</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Achieving Stability of Lipopolysaccharide-Induced NF-kappaB Activation</article-title>. <source>Science</source> <volume>309</volume> (<issue>5742</issue>), <fpage>1854</fpage>&#x2013;<lpage>1857</lpage>. <pub-id pub-id-type="doi">10.1126/science.1112304</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Das</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Amin</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Jha</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Inhibitors of Gelatinases (MMP-2 and MMP-9) for the Management of Hematological Malignancies</article-title>. <source>Eur. J. Med. Chem.</source> <volume>223</volume>, <fpage>113623</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2021.113623</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Datta</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Brunet</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>M. E.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Cellular Survival: a Play in Three Akts</article-title>. <source>Genes Dev.</source> <volume>13</volume> (<issue>22</issue>), <fpage>2905</fpage>&#x2013;<lpage>2927</lpage>. <pub-id pub-id-type="doi">10.1101/gad.13.22.2905</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>L. F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>S. X.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Z. J.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Anti-tumor Effect of Monkshood Polysaccharide with Adriamycin Long Circulating Temperature-Sensitive Liposome and its Mechanism</article-title>. <source>Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi</source> <volume>22</volume> (<issue>04</issue>), <fpage>458</fpage>&#x2013;<lpage>462</lpage>. <pub-id pub-id-type="doi">10.3321/j.issn:1007-8738.2006.04.015</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>L. F.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Miao</surname>
<given-names>Z. H.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>C. Z.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>X. L.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Y. Q.</given-names>
</name>
</person-group> (<year>2003a</year>). <article-title>Antineoplastic Effect of Monkshood Polysaccharide on Mice Transplanted with Tumor Lines of H22 and S180</article-title>. <source>J. Basic Chin. Med.</source> <volume>2003</volume> (<issue>09</issue>), <fpage>14</fpage>&#x2013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.3969/j.issn.1006-3250.2003.09.007</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>L. F.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>S. X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Z. J.</given-names>
</name>
</person-group> (<year>2003b</year>). <article-title>Cooperative Effects of Monkshood Polysaccharide with Adriamycin Magnetic Albumin Microsphere Targeting Therapy on Tumor</article-title>. <source>J. China Pharm. Univ.</source> <volume>2003</volume> (<issue>06</issue>), <fpage>68</fpage>&#x2013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.3321/j.issn:1000-5048.2003.06.016</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Deiry</surname>
<given-names>W. S.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Regulation of P53 Downstream Genes</article-title>. <source>Semin. Cancer Biol.</source> <volume>8</volume> (<issue>5</issue>), <fpage>345</fpage>&#x2013;<lpage>357</lpage>. <pub-id pub-id-type="doi">10.1006/scbi.1998.0097</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>The Anti-tumor Activity and Mechanism of Alkaloids from Aconitum Szechenyianum Gay</article-title>. <source>Bioorg. Med. Chem. Lett.</source> <volume>26</volume> (<issue>2</issue>), <fpage>380</fpage>&#x2013;<lpage>387</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2015.12.006</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Fang</surname>
<given-names>C. X.</given-names>
</name>
</person-group> (<year>2018</year>). <source>Study on the Hydrosolube Constituents of Fuzi and the Cardiotoxicity on Zebrafish</source>. <comment>Master&#x2019;s thesis</comment>. <publisher-loc>Chengdu</publisher-loc>: <publisher-name>Chengdu University of Traditional Chinese Medicine</publisher-name>. </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>H. T.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>W. W.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y. T.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X. P.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Hypaconitine Inhibits TGF-&#x392;1-Induced Epithelial-Mesenchymal Transition and Suppresses Adhesion, Migration, and Invasion of Lung Cancer A549 Cells</article-title>. <source>Chin. J. Nat. Med.</source> <volume>15</volume> (<issue>06</issue>), <fpage>427</fpage>&#x2013;<lpage>435</lpage>. <pub-id pub-id-type="doi">10.1016/S1875-5364(17)30064-X</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>Y. L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D. Q.</given-names>
</name>
<name>
<surname>Vaziri</surname>
<given-names>N. D.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y. Y.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Small Molecule Inhibitors of Epithelial-Mesenchymal Transition for the Treatment of Cancer and Fibrosis</article-title>. <source>Med. Res. Rev.</source> <volume>40</volume> (<issue>1</issue>), <fpage>54</fpage>&#x2013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1002/med.21596</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gainor</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Dardaei</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yoda</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Friboulet</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Leshchiner</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Katayama</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer</article-title>. <source>Cancer Discov.</source> <volume>6</volume> (<issue>10</issue>), <fpage>1118</fpage>&#x2013;<lpage>1133</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-16-0596</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gainor</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yoda</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dagogo-Jack</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Friboulet</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J. J.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <italic>ROS1</italic>-Positive Non-small-cell Lung Cancer</article-title>. <source>JCO Precis Oncol.</source> <volume>2017</volume> (<issue>2017</issue>), <fpage>1</fpage>&#x2013;<lpage>13</lpage>. <comment>PO.17.00063</comment>. <pub-id pub-id-type="doi">10.1200/po.17.00063</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galluzzi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pietrocola</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bravo-San Pedro</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Amaravadi</surname>
<given-names>R. K.</given-names>
</name>
<name>
<surname>Baehrecke</surname>
<given-names>E. H.</given-names>
</name>
<name>
<surname>Cecconi</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Autophagy in Malignant Transformation and Cancer Progression</article-title>. <source>EMBO J.</source> <volume>34</volume> (<issue>7</issue>), <fpage>856</fpage>&#x2013;<lpage>880</lpage>. <pub-id pub-id-type="doi">10.15252/embj.201490784</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2012a</year>). <article-title>Diterpenoid Alkaloids from the Chinese Traditional Herbal &#x201c;Fuzi&#x201d; and Their Cytotoxic Activity</article-title>. <source>Molecules</source> <volume>17</volume> (<issue>5</issue>), <fpage>5187</fpage>&#x2013;<lpage>5194</lpage>. <pub-id pub-id-type="doi">10.3390/molecules17055187</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>L. L.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>L. T.</given-names>
</name>
</person-group> (<year>2012b</year>). <article-title>Induction of Differentiation of Dendritic Cells Derived from Hepatocellular Carcinoma by Fuzi Polysaccharice</article-title>. <source>Chin. J. Clin. Oncol.</source> <volume>39</volume> (<issue>13</issue>), <fpage>882</fpage>&#x2013;<lpage>885&#x2b;894</lpage>. <pub-id pub-id-type="doi">10.3969/j.issn.1000-8179.2012.13.002</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>J. D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C. L.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Effects of Compound Aconitum Polysaccharide on Glycosylation of Tumor Cells</article-title>. <source>Zhongguo Zhong Xi Yi Jie He Za Zhi</source> <volume>36</volume> (<issue>09</issue>), <fpage>1103</fpage>&#x2013;<lpage>1106</lpage>. <pub-id pub-id-type="doi">10.7661/CJIM.2016.09.1103</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girotti</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Salatino</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dalotto-Moreno</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Rabinovich</surname>
<given-names>G. A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Sweetening the Hallmarks of Cancer: Galectins as Multifunctional Mediators of Tumor Progression</article-title>. <source>J. Exp. Med.</source> <volume>217</volume> (<issue>2</issue>), <fpage>e20182041</fpage>. <pub-id pub-id-type="doi">10.1084/jem.20182041</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gottlob</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Majewski</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kandel</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Robey</surname>
<given-names>R. B.</given-names>
</name>
<name>
<surname>Hay</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Inhibition of Early Apoptotic Events by Akt/PKB Is Dependent on the First Committed Step of Glycolysis and Mitochondrial Hexokinase</article-title>. <source>Genes Dev.</source> <volume>15</volume> (<issue>11</issue>), <fpage>1406</fpage>&#x2013;<lpage>1418</lpage>. <pub-id pub-id-type="doi">10.1101/gad.889901</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Green</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Evan</surname>
<given-names>G. I.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>A Matter of Life and Death</article-title>. <source>Cancer Cell</source> <volume>1</volume> (<issue>1</issue>), <fpage>19</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/s1535-6108(02)00024-7</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T. H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C. R.</given-names>
</name>
<name>
<surname>Fen</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Induction Effect of Mesaconitine on Apoptosis of K562 and K562/DNR Cells and Related Mechanism</article-title>. <source>Acta Medicinae Universitatis Scientiae et Technologiae Huazhong</source> <volume>46</volume> (<issue>03</issue>), <fpage>281</fpage>&#x2013;<lpage>284</lpage>. <pub-id pub-id-type="doi">10.3870/j.issn.1672-0741.2017.03.008</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Pharmacological Properties and Derivatives of Shikonin-A Review in Recent Years</article-title>. <source>Pharmacol. Res.</source> <volume>149</volume>, <fpage>104463</fpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2019.104463</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanahan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Weinberg</surname>
<given-names>R. A.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Hallmarks of Cancer: the Next Generation</article-title>. <source>Cell</source> <volume>144</volume> (<issue>5</issue>), <fpage>646</fpage>&#x2013;<lpage>674</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Hao</surname>
<given-names>W. J.</given-names>
</name>
</person-group> (<year>2014</year>). <source>Study on the Chemical Constituents of the Alkaloids from the Root of Aconitum Flavum Hand.-Mazz and its Anti-tumor Activities</source>. <comment>Master&#x2019;s thesis</comment>. <publisher-loc>Ningxia</publisher-loc>: <publisher-name>Ningxia Medical University</publisher-name>. </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hazawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kawahara</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kashiwakura</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Suppressive Effects of Novel Derivatives Prepared from Aconitum Alkaloids on Tumor Growth</article-title>. <source>Invest. New Drugs</source> <volume>27</volume> (<issue>2</issue>), <fpage>111</fpage>&#x2013;<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1007/s10637-008-9141-4</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hazawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kawahara</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kashiwakura</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Structure-activity Relationships between the Aconitum C20-Diterpenoid Alkaloid Derivatives and the Growth Suppressive Activities of Non-hodgkin&#x27;s Lymphoma Raji Cells and Human Hematopoietic Stem/progenitor Cells</article-title>. <source>Invest. New Drugs</source> <volume>29</volume> (<issue>1</issue>), <fpage>1</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s10637-009-9327-4</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hennessy</surname>
<given-names>B. T.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>D. L.</given-names>
</name>
<name>
<surname>Ram</surname>
<given-names>P. T.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mills</surname>
<given-names>G. B.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery</article-title>. <source>Nat. Rev. Drug Discov.</source> <volume>4</volume> (<issue>12</issue>), <fpage>988</fpage>&#x2013;<lpage>1004</lpage>. <pub-id pub-id-type="doi">10.1038/nrd1902</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>H&#xf6;llt</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kouba</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dietel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vogt</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>1992</year>). <article-title>Stereoisomers of Calcium Antagonists Which Differ Markedly in Their Potencies as Calcium Blockers Are Equally Effective in Modulating Drug Transport by P-Glycoprotein</article-title>. <source>Biochem. Pharmacol.</source> <volume>43</volume> (<issue>12</issue>), <fpage>2601</fpage>&#x2013;<lpage>2608</lpage>. <pub-id pub-id-type="doi">10.1016/0006-2952(92)90149-d</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>The C/EBP Homologous Protein (CHOP) Transcription Factor Functions in Endoplasmic Reticulum Stress-Induced Apoptosis and Microbial Infection</article-title>. <source>Front. Immunol.</source> <volume>9</volume>, <fpage>3083</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.03083</pub-id> </citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Isaacson</surname>
<given-names>K. J.</given-names>
</name>
<name>
<surname>Martin Jensen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Subrahmanyam</surname>
<given-names>N. B.</given-names>
</name>
<name>
<surname>Ghandehari</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Matrix-metalloproteinases as Targets for Controlled Delivery in Cancer: An Analysis of Upregulation and Expression</article-title>. <source>J. Control. Release</source> <volume>259</volume>, <fpage>62</fpage>&#x2013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2017.01.034</pub-id> </citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jantas</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pytel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mozrzymas</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Leskiewicz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Regulska</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Antkiewicz-Michaluk</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>The Attenuating Effect of Memantine on Staurosporine-, Salsolinol- and Doxorubicin-Induced Apoptosis in Human Neuroblastoma SH-Sy5y Cells</article-title>. <source>Neurochem. Int.</source> <volume>52</volume> (<issue>4-5</issue>), <fpage>864</fpage>&#x2013;<lpage>877</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2007.10.003</pub-id> </citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname>
<given-names>B. L.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>L. P.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>F. X.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>G. Z.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L. X.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Aconitine Induces Cell Apoptosis in Human Pancreatic Cancer via NF-&#x39a;b Signaling Pathway</article-title>. <source>Eur. Rev. Med. Pharmacol. Sci.</source> <volume>20</volume> (<issue>23</issue>), <fpage>4955</fpage>&#x2013;<lpage>4964</lpage>. </citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>El-Deiry</surname>
<given-names>W. S.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Overview of Cell Death Signaling Pathways</article-title>. <source>Cancer Biol. Ther.</source> <volume>4</volume> (<issue>2</issue>), <fpage>139</fpage>&#x2013;<lpage>163</lpage>. <pub-id pub-id-type="doi">10.4161/cbt.4.2.1508</pub-id> </citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>Z. Q.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>J. W.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Higenamine Enhances the Antitumor Effects of Cucurbitacin B in Breast Cancer by Inhibiting the Interaction of AKT and CDK2</article-title>. <source>Oncol. Rep.</source> <volume>40</volume> (<issue>4</issue>), <fpage>2127</fpage>&#x2013;<lpage>2136</lpage>. <pub-id pub-id-type="doi">10.3892/or.2018.6629</pub-id> </citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalkavan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>D. R.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>MOMP, Cell Suicide as a BCL-2 Family Business</article-title>. <source>Cell Death Differ</source> <volume>25</volume> (<issue>1</issue>), <fpage>46</fpage>&#x2013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1038/cdd.2017.179</pub-id> </citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karamanou</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Franchi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vynios</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Br&#xe9;zillon</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Epithelial-to-mesenchymal Transition and Invadopodia Markers in Breast Cancer: Lumican a Key Regulator</article-title>. <source>Semin. Cancer Biol.</source> <volume>62</volume>, <fpage>125</fpage>&#x2013;<lpage>133</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcancer.2019.08.003</pub-id> </citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nabavi</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Sureda</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mehterov</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gulei</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Berindan-Neagoe</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Therapeutic Potential of Songorine, a Diterpenoid Alkaloid of the Genus Aconitum</article-title>. <source>Eur. J. Med. Chem.</source> <volume>153</volume>, <fpage>29</fpage>&#x2013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2017.10.065</pub-id> </citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuntz</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Baquero</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Michie</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Dunn</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tardito</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Holyoake</surname>
<given-names>T. L.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Targeting Mitochondrial Oxidative Phosphorylation Eradicates Therapy-Resistant Chronic Myeloid Leukemia Stem Cells</article-title>. <source>Nat. Med.</source> <volume>23</volume> (<issue>10</issue>), <fpage>1234</fpage>&#x2013;<lpage>1240</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4399</pub-id> </citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lavrik</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Golks</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Krammer</surname>
<given-names>P. H.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Death Receptor Signaling</article-title>. <source>J. Cel Sci</source> <volume>118</volume> (<issue>Pt 2</issue>), <fpage>265</fpage>&#x2013;<lpage>267</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.01610</pub-id> </citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>Y. T.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>Oon</surname>
<given-names>C. E.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Molecular Targeted Therapy: Treating Cancer with Specificity</article-title>. <source>Eur. J. Pharmacol.</source> <volume>834</volume>, <fpage>188</fpage>&#x2013;<lpage>196</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2018.07.034</pub-id> </citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Letts</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Sazanov</surname>
<given-names>L. A.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Clarifying the Supercomplex: the Higher-Order Organization of the Mitochondrial Electron Transport Chain</article-title>. <source>Nat. Struct. Mol. Biol.</source> <volume>24</volume> (<issue>10</issue>), <fpage>800</fpage>&#x2013;<lpage>808</lpage>. <pub-id pub-id-type="doi">10.1038/nsmb.3460</pub-id> </citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levine</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kroemer</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Biological Functions of Autophagy Genes: A Disease Perspective</article-title>. <source>Cell</source> <volume>176</volume> (<issue>1-2</issue>), <fpage>11</fpage>&#x2013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2018.09.048</pub-id> </citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nijhawan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Budihardjo</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Srinivasula</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Alnemri</surname>
<given-names>E. S.</given-names>
</name>
<etal/>
</person-group> (<year>1997</year>). <article-title>Cytochrome C and dATP-dependent Formation of Apaf-1/caspase-9 Complex Initiates an Apoptotic Protease cascade</article-title>. <source>Cell</source> <volume>91</volume> (<issue>4</issue>), <fpage>479</fpage>&#x2013;<lpage>489</lpage>. <pub-id pub-id-type="doi">10.1016/s0092-8674(00)80434-1</pub-id> </citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X. M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>F. F.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>D. D.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>Z. G.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>P. L.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Quercetin and Aconitine Synergistically Induces the Human Cervical Carcinoma HeLa Cell Apoptosis via Endoplasmic Reticulum (ER) Stress Pathway</article-title>. <source>PloS one</source> <volume>13</volume> (<issue>1</issue>), <fpage>e0191062</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0191062</pub-id> </citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>X. L.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>C. B.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>S. C.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Chemical Components and Pharmacological Action of Aconiti Radix</article-title>. <source>Zhongguo Zhong Yao Za Zhi</source> <volume>44</volume> (<issue>12</issue>), <fpage>2433</fpage>&#x2013;<lpage>2443</lpage>. <pub-id pub-id-type="doi">10.19540/j.cnki.cjcmm.20190221.004</pub-id> </citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>L. Y.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>P. Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q. W.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Experimental Study on Antitumor Effect of Lappaconitine Hydrobromide</article-title>. <source>Traditional Chin. Med. Res.</source> <volume>18</volume> (<issue>10</issue>), <fpage>16</fpage>&#x2013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.3969/j.issn.1001-6910.2005.10.010</pub-id> </citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>List</surname>
<given-names>A. F.</given-names>
</name>
<name>
<surname>Kopecky</surname>
<given-names>K. J.</given-names>
</name>
<name>
<surname>Willman</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Head</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Persons</surname>
<given-names>D. L.</given-names>
</name>
<name>
<surname>Slovak</surname>
<given-names>M. L.</given-names>
</name>
<etal/>
</person-group> (<year>2001</year>). <article-title>Benefit of Cyclosporine Modulation of Drug Resistance in Patients with Poor-Risk Acute Myeloid Leukemia: a Southwest Oncology Group Study</article-title>. <source>Blood</source> <volume>98</volume> (<issue>12</issue>), <fpage>3212</fpage>&#x2013;<lpage>3220</lpage>. <pub-id pub-id-type="doi">10.1182/blood.v98.12.3212</pub-id> </citation>
</ref>
<ref id="B65">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>C. L.</given-names>
</name>
</person-group> (<year>2017</year>). <source>The Function of &#x3b2;3GnT8 and Polylactosamine in the Malignant Phenotype of Liver Cancer</source>. <comment>Dissertation</comment>. <publisher-loc>Suzhou</publisher-loc>: <publisher-name>Soochow University</publisher-name>. </citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X. Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X. Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y. Z.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Study on Reversing Multi-Drug Tolerance of KBV200 Cell by Aconitine</article-title>. <source>J. Basic Chin. Med.</source> <volume>10</volume>, <fpage>55</fpage>&#x2013;<lpage>57</lpage>. </citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zuo</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Research Progress on Polysaccharides of Aconitum Medico-Plants</article-title>. <source>China Pharmaceuticals</source> <volume>28</volume> (<issue>03</issue>), <fpage>1</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.3969/j.issn.1006-4931.2019.03.001</pub-id> </citation>
</ref>
<ref id="B68">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Lupeol and its Derivatives as Anticancer and Anti-inflammatory Agents: Molecular Mechanisms and Therapeutic Efficacy</article-title>. <source>Pharmacol. Res.</source> <volume>164</volume>, <fpage>105373</fpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2020.105373</pub-id> </citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Locksley</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Killeen</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lenardo</surname>
<given-names>M. J.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology</article-title>. <source>Cell</source> <volume>104</volume> (<issue>4</issue>), <fpage>487</fpage>&#x2013;<lpage>501</lpage>. <pub-id pub-id-type="doi">10.1016/s0092-8674(01)00237-9</pub-id> </citation>
</ref>
<ref id="B70">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Bu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Comparasion of Polysaccharides in Parent Root, Daughter Root and Rootlet of Aconitum Carmichaeli</article-title>. <source>Zhongguo Zhong Yao Za Zhi</source> <volume>36</volume> (<issue>09</issue>), <fpage>1154</fpage>&#x2013;<lpage>1157</lpage>. <pub-id pub-id-type="doi">10.4268/cjcmm20110909</pub-id> </citation>
</ref>
<ref id="B71">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Di</surname>
<given-names>L. Q.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Analysis of Alkaloids in <italic>Aconiti Lateralis Radix Praeparata</italic> and Prediction of Their Mechanism in the Treatment of Cancer</article-title>. <source>J. Nanjing Univ. Traditional Chin. Med.</source> <volume>37</volume> (<issue>05</issue>), <fpage>720</fpage>&#x2013;<lpage>729</lpage>. <pub-id pub-id-type="doi">10.14148/j.issn.1672-0482.2021.0720</pub-id> </citation>
</ref>
<ref id="B72">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacEwan</surname>
<given-names>D. J.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>TNF Ligands and Receptors-Aa Matter of Life and Death</article-title>. <source>Br. J. Pharmacol.</source> <volume>135</volume> (<issue>4</issue>), <fpage>855</fpage>&#x2013;<lpage>875</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjp.0704549</pub-id> </citation>
</ref>
<ref id="B73">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maheswari</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sadras</surname>
<given-names>S. R.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Licarin A Induces Cell Death by Activation of Autophagy and Apoptosis in Non-small Cell Lung Cancer Cells</article-title>. <source>Apoptosis</source> <volume>23</volume> (<issue>3-4</issue>), <fpage>210</fpage>&#x2013;<lpage>225</lpage>. <pub-id pub-id-type="doi">10.1007/s10495-018-1449-8</pub-id> </citation>
</ref>
<ref id="B74">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mari&#xf1;o</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Niso-Santano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Baehrecke</surname>
<given-names>E. H.</given-names>
</name>
<name>
<surname>Kroemer</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Self-consumption: the Interplay of Autophagy and Apoptosis</article-title>. <source>Nat. Rev. Mol. Cel Biol</source> <volume>15</volume> (<issue>2</issue>), <fpage>81</fpage>&#x2013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1038/nrm3735</pub-id> </citation>
</ref>
<ref id="B75">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mart&#xed;nez-Lim&#xf3;n</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Joaquin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Caballero</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Posas</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>de Nadal</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The P38 Pathway: From Biology to Cancer Therapy</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume> (<issue>6</issue>), <fpage>1913</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21061913</pub-id> </citation>
</ref>
<ref id="B76">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinou</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Youle</surname>
<given-names>R. J.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Mitochondria in Apoptosis: Bcl-2 Family Members and Mitochondrial Dynamics</article-title>. <source>Dev. Cel</source> <volume>21</volume> (<issue>1</issue>), <fpage>92</fpage>&#x2013;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1016/j.devcel.2011.06.017</pub-id> </citation>
</ref>
<ref id="B77">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McIlwain</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Mak</surname>
<given-names>T. W.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Caspase Functions in Cell Death and Disease</article-title>. <source>Cold Spring Harb Perspect. Biol.</source> <volume>7</volume> (<issue>4</issue>), <fpage>a026716</fpage>. <pub-id pub-id-type="doi">10.1101/cshperspect.a026716</pub-id> </citation>
</ref>
<ref id="B78">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meng-Qi Yang</surname>
<given-names>M. Q.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y. M.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>H. Y.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>Y. T.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Efficacy and Safety of Fuzi Formulae on the Treatment of Heart Failure as Complementary Therapy: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials</article-title>. <source>Evid. Based Complement. Alternat Med.</source> <volume>2019</volume>, <fpage>9728957</fpage>. <pub-id pub-id-type="doi">10.1155/2019/9728957</pub-id> </citation>
</ref>
<ref id="B79">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagao</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Koyasu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chow</surname>
<given-names>C. C. T.</given-names>
</name>
<name>
<surname>Harada</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>HIF-1-Dependent Reprogramming of Glucose Metabolic Pathway of Cancer Cells and its Therapeutic Significance</article-title>. <source>Int. J. Mol. Sci.</source> <volume>20</volume> (<issue>2</issue>), <fpage>238</fpage>. <pub-id pub-id-type="doi">10.3390/ijms20020238</pub-id> </citation>
</ref>
<ref id="B80">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oliveira-Ferrer</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Legler</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Milde-Langosch</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Role of Protein Glycosylation in Cancer Metastasis</article-title>. <source>Semin. Cancer Biol.</source> <volume>44</volume>, <fpage>141</fpage>&#x2013;<lpage>152</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcancer.2017.03.002</pub-id> </citation>
</ref>
<ref id="B81">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Onorati</surname>
<given-names>A. V.</given-names>
</name>
<name>
<surname>Dyczynski</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ojha</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Amaravadi</surname>
<given-names>R. K.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Targeting Autophagy in Cancer</article-title>. <source>Cancer</source> <volume>124</volume> (<issue>16</issue>), <fpage>3307</fpage>&#x2013;<lpage>3318</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.31335</pub-id> </citation>
</ref>
<ref id="B82">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oyadomari</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Roles of CHOP/GADD153 in Endoplasmic Reticulum Stress</article-title>. <source>Cel Death Differ</source> <volume>11</volume> (<issue>4</issue>), <fpage>381</fpage>&#x2013;<lpage>389</lpage>. <pub-id pub-id-type="doi">10.1038/sj.cdd.4401373</pub-id> </citation>
</ref>
<ref id="B83">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinho</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Reis</surname>
<given-names>C. A.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Glycosylation in Cancer: Mechanisms and Clinical Implications</article-title>. <source>Nat. Rev. Cancer</source> <volume>15</volume> (<issue>9</issue>), <fpage>540</fpage>&#x2013;<lpage>555</lpage>. <pub-id pub-id-type="doi">10.1038/nrc3982</pub-id> </citation>
</ref>
<ref id="B84">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Porporato</surname>
<given-names>P. E.</given-names>
</name>
<name>
<surname>Filigheddu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Pedro</surname>
<given-names>J. M. B.</given-names>
</name>
<name>
<surname>Kroemer</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Galluzzi</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Mitochondrial Metabolism and Cancer</article-title>. <source>Cell Res</source> <volume>28</volume> (<issue>3</issue>), <fpage>265</fpage>&#x2013;<lpage>280</lpage>. <pub-id pub-id-type="doi">10.1038/cr.2017.155</pub-id> </citation>
</ref>
<ref id="B85">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qi</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Aconitine Inhibits the Proliferation of Hepatocellular Carcinoma by Inducing Apoptosis</article-title>. <source>Int. J. Clin. Exp. Pathol.</source> <volume>11</volume> (<issue>11</issue>), <fpage>5278</fpage>&#x2013;<lpage>5289</lpage>. </citation>
</ref>
<ref id="B86">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Qian</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2015</year>). <source>The Effect and Preliminary Mechanism Study on Monkshood Polysaccharide Combined with Aconitine to the Hepatocellualar Carcinoma Cell</source>. <comment>Master&#x2019;s thesis</comment>. <publisher-loc>Nanjing</publisher-loc>: <publisher-name>Nanjing University of Chinese Medicine</publisher-name>. </citation>
</ref>
<ref id="B87">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rashid</surname>
<given-names>H. U.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Muhammad</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Research Advances on Anticancer Activities of Matrine and its Derivatives: An Updated Overview</article-title>. <source>Eur. J. Med. Chem.</source> <volume>161</volume>, <fpage>205</fpage>&#x2013;<lpage>238</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2018.10.037</pub-id> </citation>
</ref>
<ref id="B88">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname>
<given-names>M.-Y.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Q.-T.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>C.-Y.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>J.-B.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Anticancer Activities of C18-, C19-, C20-, and Bis-Diterpenoid Alkaloids Derived from Genus Aconitum</article-title>. <source>Molecules</source> <volume>22</volume> (<issue>2</issue>), <fpage>267</fpage>. <pub-id pub-id-type="doi">10.3390/molecules22020267</pub-id> </citation>
</ref>
<ref id="B89">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roberts</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Tan-Sah</surname>
<given-names>V. P.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Miyamoto</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Akt Phosphorylates HK-II at Thr-473 and Increases Mitochondrial HK-II Association to Protect Cardiomyocytes</article-title>. <source>J. Biol. Chem.</source> <volume>288</volume> (<issue>33</issue>), <fpage>23798</fpage>&#x2013;<lpage>23806</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M113.482026</pub-id> </citation>
</ref>
<ref id="B90">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruan</surname>
<given-names>Q. P.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H. L.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Isolation, Purification and Physicochemical Properties of the Polysaccharide F1 from Aconitum Carmichaeli Debx</article-title>. <source>Nat. Product. Res. Dev.</source> <volume>2000</volume> (<issue>05</issue>), <fpage>46</fpage>&#x2013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.16333/j.1001-6880.2000.05.012</pub-id> </citation>
</ref>
<ref id="B91">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanchez-Lopez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Gomez del Pulgar</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Moyer</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Lacal Sanjuan</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Cebrian</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Choline Kinase Inhibition Induces Exacerbated Endoplasmic Reticulum Stress and Triggers Apoptosis via CHOP in Cancer Cells</article-title>. <source>Cell Death Dis</source> <volume>4</volume> (<issue>11</issue>), <fpage>e933</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2013.453</pub-id> </citation>
</ref>
<ref id="B92">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X. H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Effects of Benzoylaconitine on Autophagy and Apoptosis of Human Lung Cancer Cell Line A549</article-title>. <source>China Pharm.</source> <volume>30</volume> (<issue>20</issue>), <fpage>2782</fpage>&#x2013;<lpage>2788</lpage>. <pub-id pub-id-type="doi">10.6039/j.issn.1001-0408.2019.20.10</pub-id> </citation>
</ref>
<ref id="B93">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shaw</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Cantley</surname>
<given-names>L. C.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Ras, PI(3)K and mTOR Signalling Controls Tumour Cell Growth</article-title>. <source>Nature</source> <volume>441</volume> (<issue>7092</issue>), <fpage>424</fpage>&#x2013;<lpage>430</lpage>. <pub-id pub-id-type="doi">10.1038/nature04869</pub-id> </citation>
</ref>
<ref id="B94">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheng</surname>
<given-names>L. H.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L. Q.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Cytotoxic Effect of Lappaconitine on Non-small Cell Lung Cancer <italic>In Vitro</italic> and its Molecular Mechanism</article-title>. <source>Zhong Yao Cai</source> <volume>37</volume> (<issue>05</issue>), <fpage>840</fpage>&#x2013;<lpage>843</lpage>. <pub-id pub-id-type="doi">10.13863/j.issn1001-4454.2014.05.026</pub-id> </citation>
</ref>
<ref id="B95">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Meena</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Luqman</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Baicalin Mediated Regulation of Key Signaling Pathways in Cancer</article-title>. <source>Pharmacol. Res.</source> <volume>164</volume>, <fpage>105387</fpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2020.105387</pub-id> </citation>
</ref>
<ref id="B96">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singhuber</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Prinz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kopp</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Aconitum in Traditional Chinese Medicine: a Valuable Drug or an Unpredictable Risk?</article-title> <source>J. Ethnopharmacol.</source> <volume>126</volume>, <fpage>18</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2009.07.031</pub-id> </citation>
</ref>
<ref id="B97">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bode</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>M. H.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>AKT as a Therapeutic Target for Cancer</article-title>. <source>Cancer Res.</source> <volume>79</volume> (<issue>6</issue>), <fpage>1019</fpage>&#x2013;<lpage>1031</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-2738</pub-id> </citation>
</ref>
<ref id="B98">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W. X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>A. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Analyze and Verify the Potential Anti-tumor Mechanism of Higenamine in Aconitum Carmichaeli Debx Based on the Biological Databases</article-title>. <source>J. Nanjing Univ. Traditional Chin. Med.</source> <volume>36</volume> (<issue>05</issue>), <fpage>655</fpage>&#x2013;<lpage>660</lpage>. <pub-id pub-id-type="doi">10.14148/j.issn.1672-0482.2020.0655</pub-id> </citation>
</ref>
<ref id="B99">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Storch</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kaftan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Burkhardt</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Schwarz</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>1-Methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (Salsolinol) Is Toxic to Dopaminergic Neuroblastoma SH-Sy5y Cells via Impairment of Cellular Energy Metabolism</article-title>. <source>Brain Res.</source> <volume>855</volume> (<issue>1</issue>), <fpage>67</fpage>&#x2013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/s0006-8993(99)02272-6</pub-id> </citation>
</ref>
<ref id="B100">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stuart</surname>
<given-names>S. D.</given-names>
</name>
<name>
<surname>Schauble</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>Keppler</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Bingham</surname>
<given-names>P. M.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>A Strategically Designed Small Molecule Attacks Alpha-Ketoglutarate Dehydrogenase in Tumor Cells through a Redox Process</article-title>. <source>Cancer Metab.</source> <volume>2</volume> (<issue>1</issue>), <fpage>4</fpage>. <pub-id pub-id-type="doi">10.1186/2049-3002-2-4</pub-id> </citation>
</ref>
<ref id="B101">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>Z. J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>J. F.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Anti-tumor Activity of 3-acetylaconitine and Songorine from Aconitum Szechenyianum Gay</article-title>. <source>Fine Chemicals</source> <volume>35</volume> (<issue>07</issue>), <fpage>1163</fpage>&#x2013;<lpage>1169</lpage>. <pub-id pub-id-type="doi">10.13550/j.jxhg.20170615</pub-id> </citation>
</ref>
<ref id="B102">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>M. L.</given-names>
</name>
</person-group> (<year>2017</year>). <source>Mechanism Underlying Lappaconitine Antinociception in Chronic Pain</source>. <comment>Master&#x2019;s thesis</comment>. <publisher-loc>Shanghai</publisher-loc>: <publisher-name>Shanghai Jiao Tong University</publisher-name>. </citation>
</ref>
<ref id="B103">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tabas</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ron</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Integrating the Mechanisms of Apoptosis Induced by Endoplasmic Reticulum Stress</article-title>. <source>Nat. Cel Biol</source> <volume>13</volume> (<issue>3</issue>), <fpage>184</fpage>&#x2013;<lpage>190</lpage>. <pub-id pub-id-type="doi">10.1038/ncb0311-184</pub-id> </citation>
</ref>
<ref id="B104">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L. C.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Leng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Z. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Chemical Constituents and Pharmacological Activities of Aconiti Lateralis Radix Praeparata</article-title>. <source>Guihaia</source> <volume>37</volume> (<issue>12</issue>), <fpage>1614</fpage>&#x2013;<lpage>1627</lpage>. <pub-id pub-id-type="doi">10.11931/guihaia.gxzw201704033</pub-id> </citation>
</ref>
<ref id="B105">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taniguchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Karin</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>NF-&#x3ba;B, Inflammation, Immunity and Cancer: Coming of Age</article-title>. <source>Nat. Rev. Immunol.</source> <volume>18</volume> (<issue>5</issue>), <fpage>309</fpage>&#x2013;<lpage>324</lpage>. <pub-id pub-id-type="doi">10.1038/nri.2017.142</pub-id> </citation>
</ref>
<ref id="B106">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valvona</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Fillmore</surname>
<given-names>H. L.</given-names>
</name>
<name>
<surname>Nunn</surname>
<given-names>P. B.</given-names>
</name>
<name>
<surname>Pilkington</surname>
<given-names>G. J.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>The Regulation and Function of Lactate Dehydrogenase A: Therapeutic Potential in Brain Tumor</article-title>. <source>Brain Pathol.</source> <volume>26</volume> (<issue>1</issue>), <fpage>3</fpage>&#x2013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1111/bpa.12299</pub-id> </citation>
</ref>
<ref id="B107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vandenbroucke</surname>
<given-names>R. E.</given-names>
</name>
<name>
<surname>Libert</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Is There new hope for Therapeutic Matrix Metalloproteinase Inhibition?</article-title> <source>Nat. Rev. Drug Discov.</source> <volume>13</volume> (<issue>12</issue>), <fpage>904</fpage>&#x2013;<lpage>927</lpage>. <pub-id pub-id-type="doi">10.1038/nrd4390</pub-id> </citation>
</ref>
<ref id="B108">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vasan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Werner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chandel</surname>
<given-names>N. S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Mitochondrial Metabolism as a Target for Cancer Therapy</article-title>. <source>Cell Metab</source> <volume>32</volume> (<issue>3</issue>), <fpage>341</fpage>&#x2013;<lpage>352</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2020.06.019</pub-id> </citation>
</ref>
<ref id="B109">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nihira</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hayakawa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tomita</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hayashida</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ohno</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Effects of Long-Term Administrations of Aconitine on Electrocardiogram and Tissue Concentrations of Aconitine and its Metabolites in Mice</article-title>. <source>Forensic Sci. Int.</source> <volume>148</volume>, <fpage>21</fpage>&#x2013;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1016/j.forsciint.2004.04.016</pub-id> </citation>
</ref>
<ref id="B110">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hazawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kawahara</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kashiwakura</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Inhibitory Effects of Diterpenoid Alkaloids on the Growth of A172 Human Malignant Cells</article-title>. <source>J. Nat. Prod.</source> <volume>70</volume> (<issue>12</issue>), <fpage>1854</fpage>&#x2013;<lpage>1858</lpage>. <pub-id pub-id-type="doi">10.1021/np070270w</pub-id> </citation>
</ref>
<ref id="B111">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hazawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kawahara</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kashiwakura</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Structure-activity Relationships and the Cytotoxic Effects of Novel Diterpenoid Alkaloid Derivatives against A549 Human Lung Carcinoma Cells</article-title>. <source>J. Nat. Med.</source> <volume>65</volume> (<issue>1</issue>), <fpage>43</fpage>&#x2013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1007/s11418-010-0452-3</pub-id> </citation>
</ref>
<ref id="B112">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ohkoshi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Goto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Morris-Natschke</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>K. H.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Evaluation of Aconitum Diterpenoid Alkaloids as Antiproliferative Agents</article-title>. <source>Bioorg. Med. Chem. Lett.</source> <volume>25</volume> (<issue>7</issue>), <fpage>1525</fpage>&#x2013;<lpage>1531</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2015.02.018</pub-id> </citation>
</ref>
<ref id="B113">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yamashita</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Cytotoxic Effects of Diterpenoid Alkaloids against Human Cancer Cells</article-title>. <source>Molecules</source> <volume>24</volume> (<issue>12</issue>), <fpage>2317</fpage>. <pub-id pub-id-type="doi">10.3390/molecules24122317</pub-id> </citation>
</ref>
<ref id="B114">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waghray</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment</article-title>. <source>J. Med. Chem.</source> <volume>61</volume> (<issue>12</issue>), <fpage>5108</fpage>&#x2013;<lpage>5121</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b01457</pub-id> </citation>
</ref>
<ref id="B115">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walczak</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Death Receptor-Ligand Systems in Cancer, Cell Death, and Inflammation</article-title>. <source>Cold Spring Harb Perspect. Biol.</source> <volume>5</volume> (<issue>5</issue>), <fpage>a008698</fpage>. <pub-id pub-id-type="doi">10.1101/cshperspect.a008698</pub-id> </citation>
</ref>
<ref id="B116">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wanpen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kooncumchoo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Shavali</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Govitrapong</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ebadi</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Salsolinol, an Endogenous Neurotoxin, Activates JNK and NF-kappaB Signaling Pathways in Human Neuroblastoma Cells</article-title>. <source>Neurochem. Res.</source> <volume>32</volume> (<issue>3</issue>), <fpage>443</fpage>&#x2013;<lpage>450</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-006-9246-0</pub-id> </citation>
</ref>
<ref id="B117">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warburg</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Wind</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Negelein</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>1927</year>). <article-title>THE METABOLISM OF TUMORS IN THE BODY</article-title>. <source>J. Gen. Physiol.</source> <volume>8</volume> (<issue>6</issue>), <fpage>519</fpage>&#x2013;<lpage>530</lpage>. <pub-id pub-id-type="doi">10.1085/jgp.8.6.519</pub-id> </citation>
</ref>
<ref id="B118">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wheaton</surname>
<given-names>W. W.</given-names>
</name>
<name>
<surname>Weinberg</surname>
<given-names>S. E.</given-names>
</name>
<name>
<surname>Hamanaka</surname>
<given-names>R. B.</given-names>
</name>
<name>
<surname>Soberanes</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>L. B.</given-names>
</name>
<name>
<surname>Anso</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Metformin Inhibits Mitochondrial Complex I of Cancer Cells to Reduce Tumorigenesis</article-title>. <source>Elife</source> <volume>3</volume>, <fpage>e02242</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.02242</pub-id> </citation>
</ref>
<ref id="B119">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wing</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sakaguchi</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Human FOXP3&#x2b; Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer</article-title>. <source>Immunity</source> <volume>50</volume> (<issue>2</issue>), <fpage>302</fpage>&#x2013;<lpage>316</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2019.01.020</pub-id> </citation>
</ref>
<ref id="B120">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>L. Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z. J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y. L.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X. D.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Advances in Studies on Chemical Constituents and Bioactivities of Aconitum Carmichaeli</article-title>. <source>Chin. J. Exp. Traditional Med. Formulae</source> <volume>20</volume> (<issue>02</issue>), <fpage>212</fpage>&#x2013;<lpage>220</lpage>. <pub-id pub-id-type="doi">10.11653/syfj2014020212</pub-id> </citation>
</ref>
<ref id="B121">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Z. Z.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y. F.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Z. J.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y. H.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>A Systematic Review of Pharmacokinetic Studies on Herbal Drug Fuzi: Implications for Fuzi as Personalized Medicine</article-title>. <source>Phytomedicine</source> <volume>44</volume>, <fpage>187</fpage>&#x2013;<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2018.03.001</pub-id> </citation>
</ref>
<ref id="B122">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xin Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y. F.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X. Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C. F.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Screening of Antitumor Active Components and Key Targets of Aconiti Lateralis Radix Praeparata-Pinelliae Rhizoma Based on PI3K/Akt Pathway</article-title>. <source>Chin. J. Exp. Traditional Med. Formulae</source> <volume>25</volume> (<issue>10</issue>), <fpage>170</fpage>&#x2013;<lpage>179</lpage>. <pub-id pub-id-type="doi">10.13422/j.cnki.syfjx.20191026</pub-id> </citation>
</ref>
<ref id="B123">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiong</surname>
<given-names>H. S.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L. H.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Regulatory Effects and Mechanism of Aconitine on Proliferation, Invasion and Migration of Hepatoma Carcinoma Cell MHCC97</article-title>. <source>Chin. J. Immunol.</source> <volume>34</volume> (<issue>05</issue>), <fpage>688</fpage>&#x2013;<lpage>692</lpage>. <pub-id pub-id-type="doi">10.3969/j.issn.1000-484X.2018.05.009</pub-id> </citation>
</ref>
<ref id="B124">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Geng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>F. L.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Analysis of Polysaccharide Content and Monosaccharide Composition in Different Processed Products of Aconite</article-title>. <source>Lishizhen Med. Materia Med. Res.</source> <volume>25</volume> (<issue>06</issue>), <fpage>1388</fpage>&#x2013;<lpage>1390</lpage>. <pub-id pub-id-type="doi">10.3969/j.issn.1008-0805.2014.06.041</pub-id> </citation>
</ref>
<ref id="B125">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>H. Y.</given-names>
</name>
</person-group> (<year>2020</year>). <source>Expression of TRAIL in Esophageal Squamous Cell Carcinoma Promotes Tumor Progression</source>. <comment>Master&#x2019;s thesis</comment>. <publisher-loc>Zhengzhou</publisher-loc>: <publisher-name>Zhengzhou University</publisher-name>. </citation>
</ref>
<ref id="B126">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Targeting NF-&#x39a;b Pathway for the Therapy of Diseases: Mechanism and Clinical Study</article-title>. <source>Signal. Transduct Target. Ther.</source> <volume>5</volume> (<issue>1</issue>), <fpage>209</fpage>. <pub-id pub-id-type="doi">10.1038/s41392-020-00312-6</pub-id> </citation>
</ref>
<ref id="B127">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y. M.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Research Progress on Chemical Constituents and Pharmacological Activities of C<sub>18</sub>-Diterpenoid Alkaloids</article-title>. <source>Chin. Traditional Patent Med.</source> <volume>38</volume> (<issue>05</issue>), <fpage>1109</fpage>&#x2013;<lpage>1114</lpage>. <pub-id pub-id-type="doi">10.3969/j.issn.1001-1528.2016.05.030</pub-id> </citation>
</ref>
<ref id="B128">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Fuzi Enhances Anti-tumor Efficacy of Radiotherapy on Lung Cancer</article-title>. <source>J. Cancer</source> <volume>8</volume> (<issue>19</issue>), <fpage>3945</fpage>&#x2013;<lpage>3951</lpage>. <pub-id pub-id-type="doi">10.7150/jca.22162</pub-id> </citation>
</ref>
<ref id="B129">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X. C.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Q. G.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Rong</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Research Progress on Structure and Activity of C<sub>19</sub> Diterpeneoid Alkaloids from Aconiti Lateralis Radix Praeparata</article-title>. <source>Chin. Traditional Herbal Drugs</source> <volume>51</volume> (<issue>02</issue>), <fpage>531</fpage>&#x2013;<lpage>541</lpage>. <pub-id pub-id-type="doi">10.7501/j.issn.0253-2670.2020.02.033</pub-id> </citation>
</ref>
<ref id="B130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Assessment of Reproductive Toxicity and Genotoxicity of Aconiti Lateralis Radix Praeparata and its Processed Products in Male Mice</article-title>. <source>J. Ethnopharmacol</source> <volume>275</volume>, <fpage>114102</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2021.114102</pub-id> </citation>
</ref>
<ref id="B131">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Isolation and Structural Characterization of an Immunostimulating Polysaccharide from Fuzi, Aconitum Carmichaeli</article-title>. <source>Carbohydr. Res.</source> <volume>341</volume> (<issue>4</issue>), <fpage>485</fpage>&#x2013;<lpage>491</lpage>. <pub-id pub-id-type="doi">10.1016/j.carres.2005.11.032</pub-id> </citation>
</ref>
<ref id="B132">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Therapeutic Potential of P53 Reactivation in Cervical Cancer</article-title>. <source>Crit. Rev. Oncol. Hematol.</source> <volume>157</volume>, <fpage>103182</fpage>. <pub-id pub-id-type="doi">10.1016/j.critrevonc.2020.103182</pub-id> </citation>
</ref>
<ref id="B133">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>HOXA9 Inhibits HIF-1&#x3b1;-Mediated Glycolysis through Interacting with CRIP2 to Repress Cutaneous Squamous Cell Carcinoma Development</article-title>. <source>Nat. Commun.</source> <volume>9</volume> (<issue>1</issue>), <fpage>1480</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-018-03914-5</pub-id> </citation>
</ref>
<ref id="B134">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2008</year>). <source>Studies on the Antitumor Constituents of Aconitum Vaginatum</source>. <comment>Master&#x2019;s thesis</comment>. <publisher-loc>Wuhan</publisher-loc>: <publisher-name>Huazhong University of Science and Technology</publisher-name>. </citation>
</ref>
</ref-list>
</back>
</article>